Article for dry powder inhaler with indicia on upstream end

Abstract

Disclosed herein is an inhaler article (100) for insertion into a holder to form an inhaler system for providing a compound to the lungs of a user, the inhaler article comprising a tubular body extending along a longitudinal axis from a downstream mouthpiece end (153) to an upstream end (152); the upstream end comprises an upstream element; the upstream element includes an upstream end surface; and wherein the upstream end surface comprises a colored mark (155).

Description

Technical Field

[0001] The present disclosure relates to an inhaler article for insertion into a holder to form an inhaler system for delivering an aerosolized active ingredient to the lungs of a user, wherein the inhaler article is a tubular body extending along a longitudinal axis from a downstream mouthpiece end to an upstream end, each of the downstream mouthpiece end and the upstream end having an end face, and wherein the upstream end face has indicia. Background Art

[0002] Inhaler system can have two parts: inhaler article and holder. Inhaler article can hold active ingredient. When combined, inhaler article and holder form inhaler system. Inhaler article has an upstream end inserted into the holder for use, and a downstream end or mouthpiece end. In use, the downstream end is contacted by the user's mouth. When the inhaler article is inserted into the holder, the inhaler article is activated. The inhaler article can be activated by, for example, piercing the capsule inside the inhaler article to release the pharmaceutically active powder contained in the capsule. Alternatively, the inhaler article can be activated by, for example, heating the aerosol-generating substrate contained in the inhaler article. Alternatively, the inhaler article can be activated by, for example, triggering the airflow through the inhaler system. The user "sucks" on the downstream end of the activated inhaler article. The user's suction triggers the airflow through the inhaler article, and the airflow delivers the aerosolized active ingredient to the user's lungs. Alternatively, the inhaler article can be activated by a combination of actions. For example, the user's suction can trigger the heater.

[0003] Traditional smoking articles, such as cigarettes, have an upstream end (lit end) and a downstream end (mouth end). In traditional smoking articles, since tobacco is traditionally visible at the upstream end or lit end, and the downstream end traditionally has a filter, it is easy to distinguish the upstream end from the downstream end. In traditional smoking articles, before using the inhaler article, when the user views the upstream end face, the lit end of the traditional smoking article, the user can see the tobacco contained inside the wrapper. In traditional smoking articles, before using the traditional smoking article, when the user views the downstream end face, the mouth end of the traditional smoking article, the user can see the end face of the filter packaged in the paper wrapper. For example, the end face of the filter at the downstream end can show the end face of the filter and can be presented in white. Traditional smoking articles are consumed during use. The upstream end (lit end) is consumed or burned, so that the upstream end of the traditional smoking article no longer exists and is no longer visible at the end of the smoking experience.

[0004] In traditional smoking articles, there may be colored marks on the wrapper on the outer circumference of the traditional smoking article at the downstream end or the filter end. For example, the wrapper of a traditional cigarette may be colored at the filter end. This color may be a mark of the source of the product, the strength of the product, the flavor, or other information. This mark helps consumers identify the product. Traditionally, the mark is on the outside of the article, rather than on the upstream end face or the downstream end face of the article.

[0005] Conventional smoking articles do not have an element on the upstream end of the smoking article. The upstream end of a conventional smoking article is the ignition end. The upstream end of a conventional smoking article is ignited, and the aerosol released from the combustion of the aerosol-generating substrate is inhaled. Any element at the upstream end of a conventional smoking article will be ignited, and the aerosol released by burning this element at the upstream end will be inhaled. Summary of the invention

[0006] In the dry powder inhaler article disclosed herein, the upstream end is not ignited during use. Therefore, the upstream end of the inhaler article can have a utility that is not expected in traditional smoking devices.

[0007] Inhaler articles constructed and arranged to engage with a retainer to provide aerosolized active ingredients to a user may not have a ignition end. These articles may not burn during use. The upstream end of an inhaler article constructed and arranged to engage with a retainer to provide aerosolized active ingredients may have an upstream element that provides an upstream end face of the inhaler article. The upstream end face cannot be distinguished from the downstream end face of these inhaler articles before and after use.

[0008] For example, the inhaler article can contain the active ingredient in dry powder form. If the dry powder active ingredient is contained in a capsule inside the inhaler article, the dry powder can be released when the inhaler article is engaged with the holder, the inhaler article is activated (e.g., by piercing the capsule), and the user's puff triggers an airflow through the holder and the inhaler article to entrain the dry powder active ingredient released from the capsule into the airflow to deliver the aerosolized dry powder active ingredient to the user's lungs.

[0009] Alternatively, for example, the inhaler article can contain an aerosol-generating substrate. During use, when the inhaler article containing the aerosol-generating substrate is engaged with the holder, the inhaler article can be activated by heating the aerosol-generating substrate, which releases volatile compounds from the aerosol-generating substrate, entrains the volatile compounds into the airflow, and delivers the aerosolized volatile active ingredient to the user's lungs. The aerosol-generating substrate can be, for example, tobacco.

[0010] In these two examples, the inhaler product itself can have an upstream end and a downstream end, which appear identical to the user before use. The inhaler product can have an upstream end face and a downstream end face that appear similar. That is to say, before use, the upstream end and the downstream end may appear identical. In these two examples, the inhaler product itself can have an upstream end and a downstream end that appear identical to the user after use. That is to say, after use, the upstream end and the downstream end may appear identical.

[0011] In these two examples, the upstream end, i.e. the end inserted into the retainer, may look the same before and after use. That is, the user may not be able to determine whether the inhaler product is new or used by looking at the upstream end face of the inhaler product after use. And, in these two examples, the downstream end (mouthpiece end) may look the same before and after use. That is, the user may not be able to determine whether the inhaler product is new or used by looking at the downstream end of the inhaler product after use.

[0012] Usually, inhaler products are packaged in " packaging " so that sell to the user.For example, 10,20 or more independent inhaler products can be stacked in the box so that the user can buy a plurality of inhaler products in the packaging together.Usually, a plurality of inhaler products are arranged in the packaging, wherein the downstream end is inserted in the packaging, and when the user opens the packaging, the upstream end of the inhaler products is visible to the user.Perhaps, a plurality of inhaler products can be arranged in the packaging, wherein the upstream end of the inhaler products is inserted in the packaging, and when the user opens the packaging, the downstream end of the inhaler products is visible to the user.

[0013] Usually, in order to reduce pollution, the user can take out the inhaler product from packaging, use the inhaler product, and then put the used inhaler product back to packaging.By putting the used inhaler product back to packaging instead of discarding the used inhaler product in the environment, the user has reduced pollution.Expectation reduces pollution.Yet, when the user opens the packaging to take out the next inhaler product from packaging, the user may not distinguish between new inhaler product and used inhaler product.If the user can not distinguish the new inhaler product held in the packaging and the difference between the used inhaler product that is returned to packaging, then when the user takes out the inhaler product from packaging next time, the user may mistakenly take out the used product.When the user uses the inhaler product, the used inhaler product may not provide a satisfactory experience.If the user can not distinguish the new inhaler product and the difference between the used inhaler product that is returned to packaging, then the user may be unlikely to put the used inhaler product back to packaging.If the user is unlikely to put the used inhaler product back to packaging, then the user is more likely to discard the used inhaler product in the environment.

[0014] Therefore, in order to reduce pollution, expectation provides a kind of inhaler product, it can allow the user to see the difference between the new inhaler product that holds in the packaging and the used inhaler product.A mode of indicating to the user that the inhaler product that holds in the packaging is new inhaler product or used inhaler product is to provide mark on the upstream end face or the downstream end face, or different marks are provided on the upstream end face and the downstream end face.By providing mark on one or both in the upstream end face or the downstream end face, the user can put the used inhaler product back in the packaging with the orientation opposite to the new product in the packaging.When the used inhaler product has mark on the upstream end face, the downstream end face or both, and the used inhaler product puts back in the packaging with the orientation opposite to the new product in the packaging, the inhaler product of putting back will look different from the unused inhaler product in the packaging.The user will be able to distinguish which inhaler products are new by checking the end face of the inhaler product in the packaging, and which inhaler products are used. When the user takes out the next inhaler product from the package, the user can distinguish which inhaler products in the package are unused and which inhaler products in the package are used. The user can take out the unused inhaler products from the package because the user can see at a glance which inhaler products in the package are unused due to the presence of the mark.

[0015] For example, when the inhaler product used is put back into packaging, if the inhaler product has mark on an end face, and the user puts the inhaler product used back into packaging with the orientation opposite to the new inhaler product not yet taken out from packaging, then the user can see which inhaler products held in the packaging have been used by checking the end face in the packaging, and which are not used. In this way, using visual markings, the user can distinguish new inhaler products and the used inhaler product put back into packaging. If the user can distinguish new inhaler products and the inhaler product used, then the user is more likely to put the inhaler product used back into packaging. If the user is more likely to put the inhaler product used back into packaging, then the user is unlikely to abandon the inhaler product used in the environment. Therefore, being provided with the inhaler product with mark on an end face may reduce the pollution to environment. Therefore, in order to reduce pollution, expect to provide mark on the end face of goods.

[0016] In an embodiment, the mark is a colored mark. In an embodiment, the mark is one or more symbols. The mark is something that is discernible or perceptible to the human eye. "Colored mark" means a color different from the color of the inhaler product itself. That is, the "colored mark" can be seen against the background of the inhaler product. For example, if the inhaler product is white, the colored mark is a color different from white. This is because if the mark is the same color as the color of the inhaler product, the user will not be able to see or perceive the colored mark. The "colored mark" is visible on the inhaler product. The "colored mark" may include a surface of the inhaler product whose color is different from the color of the inhaler product. The "colored mark" may be a single color (which is different from the color of the inhaler product). Alternatively, the "colored mark" may include more than one color different from the color of the inhaler product. Alternatively, the colored mark may be in the form of a symbol. The symbol may be a letter. The symbol may be a series of letters. The symbol may be a word. The symbol may be a shape. The symbol may be an emoticon. The symbol may be a color. The symbol may be a plurality of colors. Similarly, the symbol to be visible may be a color different from the inhaler product. If the color of the symbol is the same as the color of the inhaler product, the colored mark will not be visible. For example, "colored mark" can include color, such as blue, red, green, purple, yellow, black, gray or orange, or any color that is different from the intrinsic color of the inhaler product. When the inhaler product is white, the colored mark is any color except white. When the inhaler product is a color different from white, the mark can be white, because the white mark will be visible on the non-white inhaler product. In an embodiment, the mark is one or more colors indicating the source of the inhaler product. In an embodiment, the mark is one or more colors indicating the flavor of the inhaler product. In an embodiment, the mark is one or more colors indicating the strength or dosage of the inhaler product. In an embodiment, the mark is one or more symbols indicating the source of the inhaler product. In an embodiment, the mark is one or more symbols indicating the flavor of the inhaler product. In an embodiment, the mark is one or more symbols indicating the strength or dosage of the inhaler product. In an embodiment, the mark is a combination of color and symbol. In an embodiment, the mark is one or more colored symbols. In an embodiment, the colored mark is one or more symbols indicating the source of the inhaler product. In an embodiment, the colored indicia is one or more symbols indicating the flavor of the inhaler article. In an embodiment, the colored indicia is one or more symbols indicating the strength or dosage of the inhaler article.

[0017] The inhaler article can contain an active ingredient between the downstream element and the upstream element. The active ingredient can be, for example, tobacco or a tobacco-related product or a dry powder active ingredient. The dry powder active ingredient can be contained in a capsule in the inhaler article.

[0018] In an embodiment, the mark is arranged on the upstream end face of the inhaler product. Because the upstream end of the inhaler product is upstream of the active ingredient, the active ingredient does not contact with the upstream end face during use. By contrast, the active ingredient entrained in the airflow passes the downstream end face. Therefore, it is desirable to provide a mark on the upstream end face to prevent the active ingredient from contacting the mark and possibly delivering the marked material to the user.

[0019] The disclosure provides the inhaler goods that are used in the inhaler system, and said inhaler goods have mark on the upstream end surface.When the inhaler goods had the upstream element, might mark be placed on the upstream end surface, and said upstream element provides the upstream end surface that can show mark.In an embodiment, when the upstream end surface existed before and after the use of the inhaler goods, might place mark on the upstream end surface.That is to say, in an embodiment, after using the inhaler goods, when using the inhaler goods to destroy the upstream end surface, might not provide mark on the upstream end surface.

[0020] Expect to provide the inhaler product for use in the inhaler system with colored markings on the upstream end face, to help the user distinguish new inhaler product and used inhaler product.Expect to provide the inhaler product for use in the inhaler system, said inhaler product has colored markings on the upstream end face before and after the use of inhaler product.Expect to provide the inhaler product for use in the inhaler system, said inhaler product has colored markings on the upstream end face before and after the use of inhaler product visible to the user.

[0021] In addition, it is desirable to provide an inhaler product for use in an inhaler system, the inhaler product having a colored mark on the upstream end surface to provide information to the user. Such information may include information about the source, flavor, strength or other information of the inhaler product.

[0022] The present disclosure provides an inhaler article for inserting into a holder to form an inhaler system for providing a compound to a user's lungs, the inhaler article comprising a tubular body extending from a downstream mouthpiece end to an upstream end along a longitudinal axis. The upstream end has an upstream element. The upstream element has an upstream end surface. The upstream end surface includes a colored mark.

[0023] These inhaler products can be used in the inhaler system, and this inhaler system provides dry powder to the lung of user by discharging the dry powder contained in the inhaler product and entraining this dry powder in the air flow through the inhaler system to be delivered to the lung of user.These inhaler products can be used in the system, and described system provides the aerosol that releases from aerosol generation substrate by heating aerosol generation substrate, so that active ingredient is released in the air flow through the inhaler system to be delivered to the lung of user.The inhaler product with upstream element can be used in these two inhaler systems, and wherein said upstream element has the upstream end surface that comprises mark.

[0024] Two embodiments of the inhaler products with the upstream element of the upstream end face that is suitable for colored marking are provided herein.Yet, those of ordinary skill in the art will recognize that any inhaler products with the upstream end face that is suitable for colored marking will fall within the scope of the present disclosure.And in addition, the inhaler products with the upstream element of the upstream end face that is suitable for colored marking will fall within the scope of the present disclosure before and after use.

[0025] Inhaler articles for dry powder delivery

[0026] It is desirable to provide an inhaler article for use in an inhaler system designed to deliver dry powder to a user, wherein the inhaler article has an upstream element configured to reduce or minimize leakage of the dry powder or loss of a capsule containing the dry powder before and after use. For example, it is desirable to provide an inhaler article containing an active ingredient in the form of a dry powder, the inhaler article having an upstream element having an upstream element end face that is closed before and after use.

[0027] Dry powder inhaler articles are not always well suited to provide an airflow optimized for dry powder medicament delivery during use while also minimizing leakage of dry powder from the inhaler article or loss of capsules from the inhaler article before and after use.

[0028] It is desirable to provide a kind of dry powder inhaler product, it has an upstream element, the upstream element closes the upstream end of the dry powder inhaler product before and after use, and can also open during use.It is desirable to provide a kind of dry powder inhaler product, it fully closes before and after use to prevent the loss of the capsule contained in the dry powder inhaler product.It is desirable to provide a kind of dry powder inhaler product, it fully closes before and after use to prevent the loss of the dry powder contained in the capsule contained in the dry powder inhaler product.It is desirable to provide a kind of dry powder inhaler product, it fully opens during use to allow optimal airflow to pass through the dry powder inhaler product during use.It is desirable to provide a kind of dry powder inhaler product with an upstream elastic element, the upstream elastic element closes before and after use and opens during use.It is desirable to provide a kind of dry powder inhaler product with an upstream element, the upstream element closes before and after use, and has a colored mark to provide information to the user.The colored mark may include a color.The colored mark may include at least one symbol.The colored mark may include a color and at least one symbol.

[0029] The inhaler article for inserting into the holder to form an inhaler system for providing the compound to the user's lungs may include a tubular body extending from the downstream mouthpiece end to the upstream end along the longitudinal axis, the upstream end including an upstream element, the upstream element including an upstream end surface, wherein the upstream end surface includes a mark. The mark may be a colored mark. The mark may be at least one symbol. The mark may be a combination of a colored mark and at least one symbol. The mark may be at least one colored symbol. The inhaler article may be a tubular article with an upstream end and a downstream end. The upstream end may be inserted into the holder. The downstream end (mouth end) may be engaged by the user's mouth so that the dry powder can be inhaled into the user's lungs.

[0030] In an embodiment, the inhaler article contains a certain dose or multiple doses of dry powder active ingredients. The dry powder can be contained in a capsule inside the inhaler article. The inhaler article can be a disposable article. In order to use the inhaler system, the user can insert the inhaler article into a retainer, activate the system to release the dry powder from the capsule, inhale the dry powder, and then remove the used inhaler article from the retainer. The activation system can include piercing the capsule. In an embodiment, the active ingredient is nicotine.

[0031] It is expected that the inhaler article is constructed and arranged to optimize the dry powder delivery from the inhaler system to the lung of the user during use. In addition, before and after use, it is expected to ensure that the capsule and the dry powder active ingredient are safely contained in the inhaler article. In other words, it is expected that the capsule will not fall out from the inhaler article before or after use. And the dry powder held in the capsule will not fall out from the inhaler article before or after use. In addition, it is expected that the upstream end surface of the inhaler article includes colored markings so that the user can confirm the information about the inhaler article before and after use. Such information includes but is not limited to the source, flavor or intensity of the inhaler article. In addition, it is expected that the upstream end of the inhaler article is used with colored markings to distinguish new inhaler articles and used inhaler articles when the user puts the used inhaler article back into the packaging of the inhaler article. For example, if the user puts the used inhaler article back into the packaging with the orientation different from the new article held in the packaging, the user can use colored markings to distinguish new inhaler articles and used inhaler articles when the user selects the inhaler article to use. Inhaler products are preferably inhaler products, and the inhaler products are preferably inhaler products.For example, the inhaler products have colored markings on the upstream end of the inhaler products, and do not have colored markings on the downstream end of the inhaler products.All inhaler products are initially placed in the packaging with the same orientation.That is to say, the upstream end of all inhaler products is visible when the user opens the packaging.Perhaps, the downstream end of all inhaler products is visible when the user opens the packaging.Then, when the user takes out an inhaler product in the inhaler products from the packaging that holds a plurality of inhaler products, uses the inhaler products, and when the inhaler products are placed back in the packaging that holds a plurality of inhaler products with the orientation opposite to the orientation of unused inhaler products, the user can easily see which inhaler products in the packaging have been used.

[0032] Expect that the upstream end surface that comprises colored marking is visible when the inhaler product is contained in the packaging, and this packaging holds a plurality of inhaler products.Expect that at least one upstream end surface that comprises colored marking of at least one inhaler product contained in the packaging is visible when the packaging is opened.In an embodiment, when a plurality of inhaler products are arranged in the packaging, at least one inhaler product in the inhaler product is arranged in the packaging with not using orientation.In an embodiment, when a plurality of inhaler products are arranged in the packaging, at least one inhaler product in the inhaler product is arranged with having used orientation.In an embodiment, when a plurality of inhaler products are arranged in the packaging, the inhaler product is arranged in the packaging with not using orientation and having used orientation mixing.

[0033] The present disclosure provides an inhaler product with a tubular body, wherein the tubular body has an upstream element, a capsule cavity containing a capsule, a capsule containing a dry powder active ingredient, and a barrier element arranged in a linear order from an upstream end to a downstream mouthpiece end. The upstream element has an upstream end surface. The upstream element may have an elastic element. The elastic element may form the upstream end surface of the upstream element. The elastic element may be applied to the upstream end of the upstream element to form the upstream end surface of the upstream element. The elastic element may be attached to the upstream end of the tubular body. The elastic element may be attached to the upstream end surface of the upstream element of the tubular body.

[0034] The disclosure provides a kind of inhaler product, described inhaler product has elastic element at the upstream end of described inhaler product, wherein described elastic element is in closed position before being inserted in retainer, wherein described elastic element is opened to open position in response to the opening force applied to described elastic element when described inhaler product is inserted in described retainer in use, and wherein described elastic element is closed to closed position when described inhaler product is removed from described retainer after use.On the one hand, the upstream end of the pocket cavity of suction product can be the elastic element that can open closed end to form inhaler product.The disclosure provides a kind of inhaler product, it has elastic element at the upstream end of inhaler product, wherein described elastic element comprises colored marking.

[0035] The elastic element of the disclosed inhaler product is closed before and after use.May not distinguish the new inhaler product with the closed elastic element on the upstream end and the used inhaler product with the closed elastic element on the upstream end by checking the end face of the elastic element on the upstream end of the inhaler product.Might distinguish the new inhaler product and the used inhaler product by checking the end face of the elastic element on the upstream end of the inhaler product.

[0036] The elastic element of the present disclosure has the following advantages: it ensures that the capsule in the inhaler product is contained in the inhaler product before use. The elastic element opens to provide an airflow path from the upstream end of the inhaler product to the downstream mouthpiece end of the inhaler product when being inserted into the retainer. When air moves through the inhaler product, the dry powder released from the capsule is entrained in the airflow, and is delivered to the mouthpiece end of the inhaler product to be inhaled by the user. In other words, the elastic element is constructed and arranged to open during use to optimize the dry powder delivery from the inhaler system to the lung of the user. After use, when removing the inhaler product from the retainer, the elastic element is closed to keep the capsule inside the inhaler product. It is advantageous to open to provide enough airflow to deliver pharmaceutically active agents to the lung of the user when the inhaler product is inserted into the retainer during use. It is advantageous to close the inhaler product before use to prevent the capsule from falling out from the inhaler product before use. It is advantageous to close the inhaler product after use to prevent the capsule from falling out from the inhaler product after use. After the inhaler product has been activated, it is advantageous that the inhaler product fully closes after use to prevent the capsule from falling out from the inhaler product after use. The elastic element allows to open and close the upstream end of the inhaler before and after the use of the inhaler product. The elastic element can be opened to provide enough airflows when engaging with the retainer to optimize the dry powder delivery to the user's lungs, and can be closed before and after the inhaler product is inserted into the retainer to prevent the capsule from falling out from the inhaler. The elastic element on the upstream end of the inhaler product provides two advantages: realize enough airflows, and also be protected from the undesirable loss of pharmaceutically active agents from the inhaler product before and after use.

[0037] The present disclosure provides an inhaler article for inserting into a holder to form an inhaler system for providing dry powder to the lungs of a user. The inhaler article can be a tubular body extending from a downstream mouthpiece end to an upstream end along a longitudinal axis; a capsule cavity is located in the tubular body between the downstream mouthpiece end and the upstream end; and the capsule cavity accommodates a capsule. The upstream end of the inhaler article may have an elastic element. When the inhaler article is inserted into the holder, the elastic element opens to an open position in response to an opening force provided by the holder. When the inhaler article is removed from the holder, the opening force is removed from the inhaler article. When the opening force is removed from the inhaler article, the elastic element closes to a closed position, which is closed enough to keep the capsule in the capsule cavity of the inhaler article between the elastic element located at the upstream end and the downstream mouthpiece end. The elastic element is made of an elastic material suitable for opening and closing as described. The elastic element includes a colored mark.

[0038] According to one aspect of the present disclosure, the inhaler article can be a tubular body extending from a downstream mouthpiece end to an upstream end along a longitudinal axis, with a capsule cavity located within the tubular body between the downstream mouthpiece end and the upstream end, the capsule cavity accommodating the capsule. In one aspect, the downstream mouthpiece end has a barrier element. In one aspect, the barrier is a filter element. The barrier element is used to ensure that the capsule does not leave the tubular body from the downstream end before, during and after use. When the barrier is a filter, the filter element ensures that the pharmaceutically active powder delivered to the user's lungs is a powder that is small enough to pass through the filter. This ensures that the pharmaceutically active powder is suitable for delivery to the user's lungs.

[0039] According to one aspect, the elastic element is a disk. On the one hand, the elastic element is circular. On the one hand, the elastic element is an applied elastic element. The elastic element can be attached to the upstream end of the inhaler product. The elastic element can be attached to the upstream end of the inhaler product by any process suitable for attaching the elastic element to the inhaler product, and the process comprises gluing, heat sealing, pressing, friction fit or other means. The elastic element can be attached to the upstream end of the inhaler product by gluing. The elastic element can be attached to the upstream end of the inhaler product by heat sealing. The elastic element can be attached to the upstream end of the inhaler product by pressing the elastic element into the inhaler product. The elastic element can be attached to the upstream end of the inhaler product by friction fit. The elastic element can be attached to the upstream end of the inhaler product by any suitable means.

[0040] According to one aspect, the elastic element of the inhaler product is an elastic element with a flap. The elastic element can be pre-cut to form a flap. Or, the flap can be formed by assembling the flap parts together and forming an elastic element with a flap. The flap of the elastic element is folded back to provide an opening when inserted into the holder, and the opening forms an airflow path from the upstream end of the inhaler product to the downstream mouthpiece end of the inhaler product. When air moves through the inhaler product, the dry powder released from the capsule is entrained in the airflow, and is delivered to the mouthpiece end of the inhaler product to be inhaled by the user. In other words, the flap of the elastic element is opened to form a relatively large airflow aperture to optimize the dry powder delivery from the inhaler system to the lungs of the user during use. This relatively large airflow aperture allows the formation of a vortex airflow through the inhaler system, and allows the maximum release of powder from the capsule and the maximum delivery of powder to the user. After use, when removing the inhaler product from the holder, the elastic element is closed to keep the capsule inside the inhaler product. The elastic element can be pre-cut to form at least 4 flaps. The elastic element can be pre-cut to form at least 6 flaps. The elastic element can be pre-cut to form at least 8 flaps. The incision can extend between about 65% to about 95% of the diameter of the elastic element. The elastic material that is arranged at the upstream end of the inhaler product in the form of flap can be opened and closed in a way, and the mode is suitable for providing the open inhaler product when being inserted in the retainer during use, and closes to prevent the capsule from falling out from the inhaler product before and after use.

[0041] On the one hand, flap can be opened to the open position by folding the pre-cut flap into the capsule cavity of inhaler article in response to the opening force.The opening force can be provided by a retainer.That is to say, when the inhaler article is inserted in the retainer, a part of the retainer can be fitted in the upstream end inside of the inhaler article.When this part of the retainer is fitted in the inhaler article inside, the retainer can force the flap to be folded into the capsule cavity.When the flap is folded into the capsule cavity of the inhaler article, the orifice is opened, and an airflow path is formed.The elastic element with the pre-cut opening that forms the flap is opened to the open position by folding the pre-cut flap into the capsule cavity in response to the opening force.Insert the inhaler article into the retainer and an opening force can be provided, and this opening force forces the flap of the pre-cut elastic element to enter the capsule cavity of the inhaler article.

[0042] In one embodiment, the elastic element of inhaler products is an elastic element with a central aperture, and the central aperture is opened to the open position by stretching in response to the opening force. In other words, on the one hand, the elastic element of inhaler products is an annular elastic element of elastomeric material, and the annular elastic element is opened to the open position by stretching in response to the opening force. The central aperture diameter can be less than 30% of the elastic element diameter. The opening force can be provided by retainer. When the inhaler products were inserted in the retainer, the opening force could be provided by moving the tip of the retainer to the central aperture of the upstream end of the inhaler products. The inhaler products are inserted in the retainer and an opening force can be provided, and this opening force forces the central aperture to stretch in response to the opening force and open.

[0043] The elastic element of the inhaler article can be made of elastic material. The elastic element of the inhaler article can be made of, for example, silicon, latex, plastic, paper, paper tape, laminated layer PLA or cardboard on the paper layer. The elastic element can be made of silicon, latex, rubber or combination. The elastic element of the inhaler article can be made of, for example, silicon. The elastic element of the inhaler article can be made of, for example, latex. The elastic element of the inhaler article can be made of, for example, plastic. The elastic element of the inhaler article can be made of, for example, paper. The elastic element of the inhaler article can be made of, for example, aluminum foil. The elastic element of the inhaler article can be made of, for example, paper tape. The elastic element of the inhaler article can be made of, for example, laminated layer PLA on the paper layer. The elastic element of the inhaler article can be made of, for example, cardboard. The elastic element of the inhaler article can be made of, for example, rubber. The elastic element of the inhaler article can be made of, for example, a combination of materials. The elastic element of the inhaler article can be made of, for example, any suitable elastic material.

[0044] On the one hand, when the elastic element is in the open position, is engaged in the retainer, the gained opening or orifice will be provided in the capsule cavity with unrestricted or less restricted airflow.On the one hand, the retainer is configured to provide the inhaler product with a vortex or rotating inhaled airflow.On the one hand, the retainer comprises a housing that limits a housing cavity, is configured to be maintained at a removable cap in the housing cavity for the inhaler product, the removable cap can be moved in the housing cavity along the longitudinal axis of the housing, wherein the removable cap comprises a tip and a piercing end.When the inhaler product is engaged in the retainer, the tip of the removable cap extends into the elastic element at the upstream end of the inhaler product.The piercing end of the inner surface of the bottom of the retainer is attached to extend through the piercing end of the removable cap.When the removable cap moves relative to the piercing element, the inhaler product moves so that it is provided to the piercing element.The piercing element then pierces the capsule in the inhaler product to discharge pharmaceutically active dry powder from the capsule.

[0045] On the one hand, the elastic element has a mark. In an embodiment, the mark is a colored mark. In an embodiment, the mark is one or more symbols. In an embodiment, the mark is one or more colors different from the color of the inhaler product indicating the source of the inhaler product. In an embodiment, the mark is one or more colors different from the color of the inhaler product indicating the flavor of the inhaler product. In an embodiment, the mark is one or more colors different from the color of the inhaler product indicating the strength or dosage of the inhaler product. In an embodiment, the mark is one or more symbols indicating the color of the source of the inhaler product is different from the color of the inhaler product. In an embodiment, the mark is one or more symbols indicating the color of the flavor of the inhaler product is different from the color of the inhaler product. In an embodiment, the mark is one or more symbols indicating the color of the intensity or dosage of the inhaler product is different from the color of the inhaler product. "Color" can be any color. In order to become a mark, the color must be different from the color of the inhaler product. That is, if the mark is invisible against the background of the inhaler product, it cannot be seen. In order to be useful, the mark must be visible. "Color" includes white color. If the background color of the applied mark is not white, the colored mark can be white. In an embodiment, the mark is a combination of color and symbol. In an embodiment, the mark is one or more colored symbols.

[0046] Disclosed herein is an inhaler article for insertion into a holder to form an inhaler system for providing a compound to a user's lungs, the inhaler article comprising a tubular body extending along a longitudinal axis from a downstream mouthpiece end to an upstream end, the upstream end comprising an upstream element, the upstream element comprising an upstream end surface, wherein the upstream end surface comprises a colored mark. The upstream element may be a resilient element.

[0047] In one aspect, the capsule contains a pharmaceutically active dry powder. The pharmaceutically active dry powder can be nicotine.

[0048] In a dry powder inhaler system, the system is used to provide pharmaceutically active dry powder to the lungs of a user. The present disclosure provides a system, and in particular an inhaler product, which is constructed and arranged to contain active dry powder before and after use, and allows the dry powder to leave the inhaler product or be delivered from the inhaler product during use. The inhaler product has two ends: an upstream end and a downstream end. The downstream end is a mouthpiece end. The upstream end has an upstream end face, and the upstream end face has a colored mark. During use, the user places the downstream end of the inhaler product in the user's mouth and inhales.

[0049] The upstream end of inhaler product is inserted in the retainer during use.When the upstream end of inhaler product is inserted in the retainer, the upstream end of inhaler product is opened.When the upstream end of inhaler product is inserted in the retainer, inhaler product adds retainer to form inhaler system.Inhaler product is inserted in the retainer during use.The upstream end of inhaler product is opened during use to allow air flow through inhaler product and pharmaceutically active dry powder is discharged to the user.When inhaler product is inserted in the retainer, the upstream end of inhaler product is opened.Retainer provides opening force to open inhaler product to inhaler product, thereby discharges pharmaceutically active powder from inhaler product during use.

[0050] In order to prevent the pharmaceutically active dry powder from falling out from the inhaler product before use, the upstream end of the inhaler product is closed before use. After use, after the inhaler product is removed from the retainer, the upstream end of the inhaler product is closed to prevent the pharmaceutically active dry powder from falling out from the inhaler after use. The upstream end of the inhaler product is opened when the inhaler product is inserted into the retainer, and is closed before and after the inhaler product is inserted into the retainer.

[0051] In order to make the upstream end of inhaler products can be closed before use, open during use and then close again after use, the upstream end of inhaler products is a resilient element.The resilient element is closed before use, opens during use, and then returns to the closed position after use.The resilient element is closed before use, opens when the inhaler products are inserted in the retainer, and then closes again when the inhaler products are removed from the retainer.The resilient element can be colored, or can have one or more symbols, or can have color and one or more symbols.Color and symbol are marks.These marks that exist separately or in combination convey information to the user.

[0052] Inhaler products can be any shape or size. For ease of insertion into the retainer, inhaler products can be tubular products. Inhaler products can be tubular bodies extending from the downstream mouthpiece end to the upstream end along the longitudinal axis. Inhaler products can be cylindrical. Inhaler products contain pharmaceutically active powders.

[0053] The size and shape of the inhaler article can be similar to a smoking article or a cigarette. The inhaler article can be a tubular body extending along the longitudinal axis of the inhaler article. The inhaler article can have a substantially consistent external diameter along the length of the elongated body. The inhaler body can have a circular cross-section that can be consistent along the length of the elongated body. The inhaler body can have an external diameter in the range of about 6mm to about 10mm, or about 7mm to about 10mm, or about 7mm to about 9mm, or about 7mm to about 8mm, or about 7.2mm. The inhaler body can have a length (along the longitudinal axis) in the range of about 40mm to about 80mm, or about 40mm to about 70mm, or about 40mm to about 50mm, or about 45mm.

[0054] The inhaler article may be a tubular body extending from a downstream mouthpiece end to an upstream end along a longitudinal axis. Between the downstream mouthpiece end and the upstream end is a central cavity.

[0055] The downstream end of the inhaler product is a mouthpiece end. That is, the downstream end of the inhaler product is intended to engage with the user's mouth to allow the user to inhale the contents of the inhaler product. The downstream end is constructed and arranged to engage with the user's mouth. The size and shape of the downstream end are set to engage with the user's mouth. The downstream end of the inhaler product serves as a conduit to provide pharmaceutically active powder to the user's mouth and lungs. The downstream end of the inhaler product has a certain rigidity or hardness, size and shape to engage with the user's mouth. The downstream end of the inhaler product may have a barrier. The barrier may be an element of the inhaler product providing rigidity or hardness. The rigidity or hardness of the barrier is suitable for being inserted into the user's mouth during the use of the inhaler system. The barrier may have a size and shape to engage with the user's mouth.

[0056] In addition, the barrier may be a filter element. The filter element may have an internal structure that allows smaller particles to flow through the filter element and prevents larger particles from flowing through the filter element. The filter element may be used to filter larger particles of pharmaceutically active powder as they flow out of the inhaler article. The filter element may be used to control the size of the particles of pharmaceutically active powder as they flow out of the inhaler article. The filter element may allow particles of pharmaceutically active powder to flow out of the inhaler article to the user. The filter element may allow particles of pharmaceutically active powder to be small enough to flow out of the inhaler article through the filter element to reach the user. The filter element may be formed of cellulose acetate material. The filter element may be cellulose tow. The filter may be formed of biodegradable material.

[0057] The barrier element can extend from the central cavity to the mouthpiece end of the inhaler article. The barrier element can extend from the capsule cavity to the mouthpiece end of the inhaler article. The filter element can have a length in the range of about 10 mm to about 30 mm, preferably about 15 mm to about 25 mm, and more preferably about 20 mm to about 22 mm.

[0058] Inhaler article has an upstream end. The upstream end has an upstream element. The upstream element can be an elastic element. The elastic element of the inhaler article can have an incision, which allows the elastic element to open when the tip is inserted into the elastic element. These incisions can be called incisions or pre-incisions. These incisions can be described as radial incisions or diameter incisions. Two diameter incisions cause four flaps to be formed in the elastic element. Two diameter incisions that partially extend across the diameter of the elastic element are identical with four radial incisions that partially extend across the radius of the elastic element. The incision can extend in the range of about 65% to about 95% of the diameter of the elastic element. The incision can extend in the range of 65% to 95% of the diameter of the elastic element. Alternatively, the flap can be manufactured by assembling the parts together to form a flap.

[0059] When the inhaler product with the elastic element with notch (and flap) is inserted into the retainer, the tip of the retainer pushes the flap into the inside of the inhaler product. When the tip of the retainer pushes the flap into the inside of the inhaler product, the inhaler product opens. The tip of the retainer provides the opening force to open the upstream end of the inhaler product. When the inhaler product opens, the airflow path that improves the airflow through the inhaler system is provided. When the inhaler product is extracted from the retainer, the tip is extracted from the inhaler product, and the flap returns to its position at the upstream end of the inhaler product. When the opening force is withdrawn, the inhaler product is closed. When the inhaler product is removed from the retainer, the opening force is removed from the upstream end of the inhaler product. When the opening force is removed from the inhaler product, the elastic element returns to the closed position. When removing the opening force, the elastic element is closed to the closed position. Although the elastic element with notch and flap may not be completely closed before or after use, it is partially closed before and after use. The elastic element does not open after use.

[0060] The elastic element of inhaler product can have a central aperture, and the central aperture opens to the open position by stretching and opening in response to the opening force. In other words, on the one hand, the elastic element of inhaler product is an annular elastic element of elastomeric material, and the annular elastic element opens to the open position by stretching and opening in response to the opening force. The central aperture diameter can be less than 30% of the elastic element diameter. The opening force can be provided by a retainer. When the inhaler product is inserted into the retainer, the opening force can be provided by moving the tip of the retainer into the central aperture of the upstream end of the inhaler product. The inhaler product is inserted into the retainer and an opening force can be provided, and this opening force forces the central aperture to stretch and open in response to the opening force. In addition, when removing the opening force, the elastic element returns to the closed position. When removing the opening force from the retainer, the opening force is removed from the upstream end of the inhaler product. When removing the opening force from the inhaler product, the elastic element returns to the closed position. When removing the opening force, the elastic element is closed to the closed position. Although the elastic element with the central aperture may not be completely closed before or after use, it is partially closed before and after use. It will not open after use.

[0061] The elastic element of inhaler goods can have the combination of otch and center aperture, and described center aperture opens to open position by stretching and opening in response to opening force.In other words, on the one hand, the elastic element of inhaler goods is the annular elastic element of elastomeric material, and described annular elastic element opens to open position by stretching and opening in response to opening force.The center aperture diameter can be less than 30% of the elastic element diameter.Otch can extend in the scope of 65% to 95% of the diameter of elastic element.Opening force can be provided by retainer.When inhaler goods is inserted in the retainer, opening force can be provided by the tip of retainer being moved to the center aperture of the upstream end of inhaler goods.Inhaler goods is inserted in the retainer and opening force can be provided, and this opening force forces the center aperture to stretch and open in response to opening force.

[0062] When the inhaler goods were removed from retainer, the tip was removed from the inhaler goods, and the elastic element was closed.When the inhaler goods were removed from retainer, the opening force was removed.When the tip was removed from the inhaler goods, the opening force was removed.When the opening force was removed, the elastic element was closed.When removing the inhaler goods from retainer, the opening force was removed from the upstream end of the inhaler goods.When removing the opening force from the inhaler goods, the elastic element returned to the closed position.When removing the opening force, the elastic element was closed to the closed position.When removing from retainer, the colored marking on the upstream end surface of the closing elastic element was visible.

[0063] Between the downstream and upstream ends of the tubular body is a central cavity containing the pharmaceutically active powder. The central cavity may have a length ranging from about 3 mm to about 12 mm, or from about 3 mm to about 7 mm, or from about 4 mm to about 6 mm, or about 5 mm.

[0064] The cavity can contain the pharmaceutically active powder contained in the capsule. When the cavity contains the pharmaceutically active powder contained in the capsule, the cavity is a capsule cavity.

[0065] The cyst cavity can be the inside of the inhaler product between the downstream barrier element and the upstream elastic element. The downstream barrier element can be connected with the upstream elastic element by a wrapper. The wrapper can form the tubular body of the inhaler product. The tubular body limiting the cyst cavity can be formed by biodegradable materials, for example cardboard or paperboard.

[0066] The sac cavity may have an inner diameter in the range of about 6 mm to about 7 mm, or about 6.5 mm to about 6.7 mm. The sac cavity may have a transverse length in the range of about 15 mm to about 30 mm, or about 20 mm to about 25 mm.

[0067] The capsule cavity can define a cylindrical space configured to accommodate a capsule (e.g., the capsule can have an oblong shape or a circular cross-section). The capsule cavity can have a substantially uniform or uniform diameter along the length of the capsule cavity. The capsule cavity can have a fixed cavity length. The capsule cavity has a cavity inner diameter orthogonal to the longitudinal axis, and the capsule has a capsule outer diameter. The capsule cavity can be sized to accommodate an oblong capsule. The capsule cavity can have a substantially cylindrical or cylindrical cross-section along the length of the capsule cavity. The capsule cavity can have a uniform inner diameter. The capsule can have an outer diameter that is about 80% to about 95% of the inner diameter of the capsule cavity. The configuration of the capsule cavity relative to the capsule can facilitate limited movement of the capsule during activation or puncture of the capsule.

[0068] The capsule cavity can promote capsule to rotate stably in the capsule cavity relative to the structure of the capsule. During suction, the longitudinal axis of the capsule can coaxially stably rotate with the longitudinal axis of the inhaler body. The capsule cavity can promote capsule to rotate with certain shaking in the capsule cavity relative to the structure of the capsule.

[0069] Stable rotation refers to that the longitudinal axis of the inhaler body is substantially parallel or coaxial with the rotation axis of the capsule. Stable rotation may refer to that the rotating capsule does not have advancement. Preferably, the longitudinal axis of the inhaler body may be substantially coextensive with the rotation axis of the capsule. The stable rotation of the capsule may provide uniform entrainment of a portion of nicotine particles from the capsule during two or more, or five or more, or ten or more "puffing" or suction of the consumer.

[0070] The capsule can be contained in the inhaler article before consumption. The inhaler article can be contained in the capsule cavity by the elastic member.

[0071] The capsule may be formed of an airtight material that can be pierced or punctured by a piercing element that can be alone or in combination with an inhaler. The capsule may be formed of a metal or polymer material that is used to keep the capsule from contamination and can be pierced or punctured by a piercing element before consuming the nicotine particles in the capsule. The capsule may be formed of a polymer material. The polymer material may be hydroxypropyl methylcellulose (HPMC). The capsule may be a size 1 to size 4 capsule, or a size 3 capsule.

[0072] The capsule contains pharmaceutically active particles. The pharmaceutically active particles may contain nicotine (also referred to as "nicotine powder" or "nicotine particles"), and optionally contain particles of flavor (also referred to as "flavor particles"). The capsule may contain a predetermined amount of nicotine particles and optional flavor particles. The capsule may contain enough nicotine particles to provide at least 2 inhalations or "puffs", or at least about 5 inhalations or "puffs", or at least about 10 inhalations or "puffs". The capsule may contain enough nicotine particles to provide about 5 to about 50 inhalations or "puffs", or about 10 to about 30 inhalations or "puffs". Each inhalation or "puff" may deliver about 0.1 mg to about 3 mg of nicotine particles to the user's lungs, or deliver about 0.2 mg to about 2 mg of nicotine particles to the user's lungs, or deliver about 1 mg of nicotine particles to the user's lungs.

[0073] The nicotine particles can have any effective nicotine concentration based on the specific formulation used. The nicotine particles can have at least about 1%wt of nicotine up to about 30%wt of nicotine, or about 2%wt to about 25%wt of nicotine, or about 3%wt to about 20%wt of nicotine, or about 4%wt to about 15%wt of nicotine, or about 5%wt to about 13%wt of nicotine. Preferably, each inhalation or "puffing" can deliver about 50 to about 150 micrograms of nicotine to the user's lungs.

[0074] The capsule can hold or contain at least about 5 mg of nicotine particles or at least about 10 mg of nicotine particles. The capsule can hold or contain less than about 900 mg of nicotine particles, or less than about 300 mg of nicotine particles, or less than 150 mg of nicotine particles. The capsule can hold or contain about 5 mg to about 300 mg of nicotine particles or about 10 mg to about 200 mg of nicotine particles.

[0075] The nicotine particles may have any effective particle size distribution so as to be preferably delivered for inhalation into the lungs of the user. The capsule may include particles other than nicotine particles. The nicotine particles and other particles may form a powder system.

[0076] The filter element can provide a structure that allows particles of a desired size to pass through, while preventing particles of a larger size from passing through the filter. For example, the filter element can allow dry powders having an average diameter of about 60 microns or less to pass through the filter element, while preventing dry powders having an average diameter greater than about 60 microns from passing through. Alternatively, if flavor particles are desired, the filter element can provide a structure that allows particles of up to 200 microns to pass through the filter.

[0077] The nicotine or nicotine particles in the powder system can be pharmaceutically acceptable free base nicotine or nicotine salt or nicotine hydrate. Effective nicotine salt or nicotine hydrate includes, for example, nicotine pyruvate, nicotine citrate, nicotine aspartate, nicotine lactate, nicotine bitartrate, nicotine salicylate, nicotine fumarate, nicotine monopyruvate, nicotine glutamate or nicotine hydrochloride. The compound that forms a salt or hydrated salt in combination with nicotine can be selected based on its expected pharmacological effect.

[0078] Preferably, the nicotine particles include amino acids. Preferably, the amino acids can be leucine, such as L-leucine. Providing amino acids such as L-leucine to particles containing nicotine can reduce the adhesion of particles containing nicotine, and can reduce the attraction between nicotine particles and therefore reduce the agglomeration of nicotine particles. Similarly, the adhesion with particles containing fragrance can also be reduced, so the agglomeration of nicotine particles and fragrance particles is also reduced. Therefore, even when nicotine particles are combined with fragrance particles, the powder system described herein can also be a free-flowing material and have a stable relative particle size of each powder component.

[0079] Nicotine can be a surface-modified nicotine salt, wherein the nicotine salt particles include coated or composite particles. A preferred coated or composite material can be L-leucine. A particularly effective nicotine particle can be nicotine bitartrate combined with L-leucine.

[0080] The holder for inhaler products comprises: housing, the housing comprises a housing cavity for receiving the inhaler products; a removable cap, the removable cap enables the inhaler products to engage with a piercing element; a piercing element, a pointed tip, which is inserted into the upstream end of the inhaler products when the inhaler products are inserted into the holder; and an air inlet and an air flow path, the air inlet and the air flow path enable vortex airflow to pass through the inhaler products when the inhaler products are engaged in the holder. The vortex or rotating inhaled airflow can be transmitted to the inhaler products to rotate and agitate the capsule and release the dry powder contained in the capsule. The holder has an open end and a piercing end. The housing cavity is sized to receive the inhaler products. The inhaler products are inserted into the open end.

[0081] The holder has a piercing element. The piercing element is attached to the inside of the bottom surface of the holder. The piercing element length can be any suitable length relative to the housing length. For example, the piercing element length can be about 25% to about 60% of the housing length, or about 30% to about 50%. The far end of the piercing element can be fixed to the far end adjacent to the housing or at the far end of the housing. The whole length of the piercing element can be coextensive within the housing length. The piercing element is formed by a rigid material. The rigid material has enough rigidity to pierce, puncture or activate the capsule contained in the inhaler product. The piercing element can be formed by metal. The piercing element can be, for example, formed by stainless steel, such as 316 stainless steel. The piercing element can be formed by a polymer material. The piercing element can be formed by a fiber-reinforced polymer material.

[0082] The piercing element extends through the removable cap. The removable cap is movable relative to the piercing element. When the inhaler article is inserted into the holder and pressed downward, the removable cap moves downward into the holder, thereby exposing the piercing element. When the inhaler article is pressed downward against the removable cap, the piercing element extends into the inhaler article and pierces the capsule. Piercing the capsule activates the capsule. Piercing the capsule activates the inhaler system. Piercing the capsule allows powder to be released from the capsule.

[0083] When the inhaler product is inserted into the retainer, a part of the retainer is inserted into the upstream end of the inhaler product to open the upstream end of the inhaler product. When a part of the retainer is inserted into the upstream end of the inhaler product, the retainer provides the inhaler product with an opening force. In an embodiment, the part of the retainer that is inserted into the upstream end of the inhaler product is a tip. When the inhaler product is inserted into the retainer, the tip of the retainer is inserted into the upstream end of the inhaler product. When the tip of the retainer is inserted into the upstream end of the inhaler product, the tip provides the inhaler product with an opening force. When the tip of the retainer is inserted into the upstream end of the inhaler product, the upstream end of the inhaler product opens. When the tip of the retainer is inserted into the upstream end of the inhaler product, an opening force is applied to the upstream end of the inhaler product. When the tip of the retainer is inserted into the upstream end of the inhaler product as an elastic element, the elastic element opens. When removing the inhaler product from the retainer, the opening force is removed from the upstream end of the inhaler product. When removing the opening force from the inhaler product, the elastic element returns to the closed position. When the opening force is removed, the resilient element closes to the closed position.

[0084] When the inhaler product was inserted in the retainer, the part of the retainer was inserted into the elastic element at the upstream end of the inhaler product to open the elastic element of the inhaler product. When the part of the retainer was inserted into the elastic element of the inhaler product, the retainer provided the opening force to the inhaler product. When the part of the retainer was inserted into the elastic element of the inhaler product, the retainer provided the opening force to the elastic element. When the part of the retainer was inserted into the upstream end of the inhaler product, the retainer provided the opening force to the upstream end of the inhaler product. When removing the inhaler product from the retainer, the opening force was removed from the upstream end of the inhaler product. When removing the opening force from the inhaler product, the elastic element returned to the closed position. When removing the opening force, the elastic element was closed to the closed position.

[0085] The shape and size of the tip can be set to optimize the upstream end that is inserted into the inhaler product.The shape and size of the tip can be set to optimize the elastic element that is inserted into the inhaler product.For example, when the elastic element has a central aperture, the tip can be angled to optimize the expansion of the elastic element that is inserted into the central aperture. Two or more tips can be present.For example, 2 tips can be present. Three tips can be present. Four tips can be present. Five tips can be present. Six tips can be present. There may be more than six tips. Perhaps, the tip can mean the annular ring that is inserted into the upstream end of the inhaler product. Perhaps, the tip can mean the annular ring that is inserted into the elastic element of the inhaler product.

[0086] The housing can be formed of any rigid material. The housing can be formed of a polymer material. The polymer material that can be used to form the housing includes polycarbonate, polypropylene, polyethylene, nylon, acrylonitrile-butadiene-styrene, styrene-acrylonitrile, polyacrylate, polystyrene, PBT polyester, PET polyester, polyoxymethylene, polysulfone, polyethersulfone, polyetheretherketone or liquid crystal polymer.

[0087] The present disclosure provides an inhaler product having a pharmaceutically active dry powder contained in a capsule. An inhaler product containing a capsule is disclosed herein, and the capsule contains a pharmaceutically active powder. In an embodiment, the pharmaceutically active powder contains nicotine, but other pharmaceutically active powders are contemplated in the present disclosure, as described below. When a user inhales from the mouthpiece end (downstream end, proximal end) of the inhaler product, the inhaler product can be used to deliver the pharmaceutically active powder to the user. In order to deliver the pharmaceutically active dry powder contained in the capsule to the user, the pharmaceutically active powder is released from the capsule, the powder is aerosolized, and inhaled by the user. That is, when the user inhales from the mouthpiece end (downstream end, proximal end) of the inhaler product, the powder is released from the capsule and entrained into the airflow generated by the user.

[0088] According to the present disclosure, an inhaler article has a tubular body extending from a downstream mouthpiece end to an upstream end along a longitudinal axis. The interior of the tubular body is a capsule cavity. The capsule cavity contains a capsule containing a pharmaceutically active powder.

[0089] In order to release the pharmaceutically active powder from the capsule contained in the capsule cavity of the inhaler product, the capsule must be opened in a manner that allows the powder contained inside the capsule to be released. In an embodiment, the capsule is pierced. When the capsule is pierced, a hole is introduced into the capsule. This release step or piercing step can also be considered as "activation". According to the present disclosure, when the capsule is pierced by a piercing element, the capsule is activated. In an embodiment, the piercing element is located in a retainer.

[0090] In the case of the inhaler product being inserted into the retainer, the upstream end of the inhaler product is inserted into the retainer. When the inhaler product is inserted into the retainer, the inhaler product can be pressed downwards against the piercing element in the retainer, and the capsule can be pierced by the piercing element. Once inserted, the downstream end of the inhaler product extends from the retainer, and can be approached by the user's mouth. Once the capsule has been pierced or activated, the powder held in the capsule can be discharged from the capsule. The powder from the capsule can then be discharged into the airflow and sucked by the user. The inhaler product is inserted into the retainer to form an inhaler system, and the capsule is pierced by the piercing element of the retainer, and the airflow is triggered by the user, and the airflow passes the inhaler product, and the entrainment powder released from the capsule, and the pharmaceutically active powder is delivered to the user's mouth.

[0091] Retainer is separated from inhaler product, but consumer can utilize inhaler product and retainer, consume the particle of releasing in inhaler product simultaneously.A plurality of these inhaler products can be combined with retainer to form system or kit.Single retainer can be utilized on 10 or more or 25 or more or 50 or more or 100 or more inhaler products, to activate the capsule that (pierces or pierces) each inhaler product holds and reliable activation is provided.

[0092] The holder for inhaler product comprises housing, and this housing comprises housing cavity for receiving inhaler product and is configured to keep inhaler product in housing cavity.Removable cap is located in housing cavity, and can move along the longitudinal axis of housing in housing cavity.Removable cap has tip.The tip of removable cap is configured to insert into inhaler product when inhaler product is introduced into holder.Removable cap is configured to move relative to piercing element.When inhaler product is introduced into housing cavity of holder, inhaler product is pressed down into holder.When inhaler product is pressed into housing cavity, the tip of removable cap is inserted into the upstream end of inhaler product.Meanwhile, inhaler product is pressed down into housing against removable cap.Removable cap moves downward.Piercing element extends through removable cap when removable cap moves, so that the capsule inside inhaler product contacts piercing element and is pierced by piercing element.Then release inhaler product, and removable cap moves back to static position.Removable cap can move back to static position by means of spring. In the following Figure 2 The inhaler article is shown in the position of being inserted into the holder after the capsule has been pierced.

[0093] The tip of the removable cap can be inserted into the upstream end of the inhaler article through the resilient element at the upstream end of the inhaler article.

[0094] A method comprising: removing an unused inhaler article from a package, wherein the unused inhaler article is in an unused orientation in the package; inserting the inhaler article into a housing cavity of a holder to form an inhaler system; activating the inhaler article to entrain an active ingredient into an airflow through the inhaler system; delivering the active ingredient to the lungs of a user; removing the inhaler article from the holder; and placing the inhaler article back into the package in an orientation opposite to the unused orientation. Another unused inhaler article may then be inserted into the holder, and the method may be repeated.

[0095] The inhaler product associated with the above-mentioned retainer is configured to directly receive the vortex suction airflow into the far end of the inhaler product. When the user "sucks" on the downstream end of the inhaler product inserted in the retainer, the vortex suction airflow is caused. This produces negative pressure inside the inhaler product. Due to this negative pressure, air enters the retainer via the air inlet. Then, the air advances through the air path in the retainer. When the inhaler product is inserted into the retainer, the air path in the retainer guides air into the inhaler product at an angle tangent to the longitudinal axis of the inhaler product. When the inhaler product is inserted into the retainer, this tangential air produces vortex airflow in the inhaler product. This vortex airflow rotates and / or stirs the capsule in the inhaler product. This stirring of the capsule improves the flow of the activated capsule of the powder, and improves the efficiency of the powder entrainment in the airflow delivered to the user.

[0096] The elastic element may be made of any material suitable for opening and closing. For example, the elastic element may be made of silicon. The elastic element may be made of latex. The elastic element may be made of rubber. The elastic element may be made of plastic. The elastic element may be made of paper. The elastic element may be made of aluminum foil. The elastic element may be made of a laminated layer of PLA on a paper layer. The elastic element may be made of cardboard. The elastic element may be made of silicon, latex or rubber. The elastic element may be made of silicon, latex, rubber or a combination thereof.

[0097] The elastic element can be attached to the inhaler product. The elastic element can be attached to the inhaler product by any means. For example, the elastic element can be attached to the inhaler product by gluing, friction fit, heat sealing or by any means.

[0098] Inhaler articles for use in heated inhaler systems

[0099] Also disclosed herein is an inhaler article for inserting into a holder to form an inhaler system for providing a compound to a user's lungs, wherein the inhaler system includes a heater for generating an aerosol from an aerosol-generating substrate. Such an inhaler system is disclosed, for example, in WO2021170667, which is incorporated herein in its entirety.

[0100] For example, in a heated inhaler system, the tubular body of the inhaler article includes an upstream element, a strip of aerosol-generating substrate located downstream of the upstream element, an aerosol-cooling element located downstream of the support element, a mouthpiece element located downstream of the aerosol-cooling element, and an outer wrapper defining the upstream element, the aerosol-cooling element, and the mouthpiece element, arranged in linear order from an upstream end to a downstream mouthpiece end. The upstream element has an upstream end face, and the upstream end face has a colored mark.

[0101] As in the dry powder inhaler system, the heated inhaler system does not need the end of the inhaler article to be ignited. Instead, the upstream end is inserted into the retainer, and the retainer provides heat to the strip of the aerosol generating substrate. In the heated aerosol generating article, aerosol is generated by heating an aerosol generating substrate such as tobacco. Known heated aerosol generating articles include for example electrically heated aerosol generating inhaler articles, and wherein the aerosol generating articles that generate aerosol by heat transfer from a heat source to physically independent aerosol forming materials. When the aerosol generating substrate is heated in the heated inhaler article, aerosol is generated by heating an aerosol generating substrate such as tobacco. For example, in the aerosol generating system comprising an electrically heated aerosol generating device, the electrically heated aerosol generating device has an internal heater blade, and the internal heater blade is suitable for being inserted into the strip of the aerosol generating substrate. In an embodiment, the internal heater blade is inserted into the strip of the aerosol generating substrate to heat the aerosol generating substrate by conduction. In an embodiment, the internal heater blade is a susceptor that is heated by induction from a magnetic field in or generated by the holder.In an embodiment, the susceptor is located in a strip of aerosol-generating substrate in an inhaler article.

[0102] The present invention discloses an inhaler article for inserting into a holder to form an inhaler system for providing a compound to a user's lungs, the inhaler article comprising a tubular body extending from a downstream mouthpiece end to an upstream end along a longitudinal axis. The upstream end comprises an upstream element. The upstream element provides a barrier between the active ingredient and the upstream end face of the inhaler article. The upstream element prevents contact with an aerosol generating substrate. The upstream element can prevent the strip of the aerosol generating substrate from falling out of the inhaler article. The upstream element can prevent direct contact with a susceptor contained in the strip of the aerosol generating substrate. This helps prevent displacement or deformation of the susceptor element during handling or transporting the inhaler article. This in turn helps fix the form and position of the susceptor element. The upstream element can prevent the susceptor contained in the strip of the aerosol generating substrate from falling out of the inhaler article.

[0103] The upstream element may be a porous rod element. Preferably, the porous rod element does not change the suction resistance of the aerosol generating article. Preferably, the upstream element has a porosity of at least about 50% in the longitudinal direction of the aerosol generating article. Alternatively, in an embodiment, the upstream element has a porosity between about 50% and about 90% in the longitudinal direction. The porosity of the upstream element in the longitudinal direction is defined by the ratio of the cross-sectional area of ​​the material forming the upstream element to the internal cross-sectional area of ​​the aerosol generating article at the position of the upstream element. In an embodiment, the upstream element may be formed by a material that is impermeable to air. In such embodiments, the aerosol generating article may be configured so that air flows into the strip of the aerosol generating substrate through a suitable ventilation device provided in the packaging. The upstream element may be made of any material suitable for use in an inhaler article. The upstream element may, for example, be made of the same material used by one of the other components of the inhaler article (e.g., a barrier or a filter). Suitable materials for forming the upstream element include filter materials, ceramics, polymer materials, cellulose acetate, cardboard or zeolites. The upstream element may be formed by, for example, a cellulose acetate rod.

[0104] The upstream element can be formed by heat-resistant material. For example, the upstream element can be formed by a material that tolerates temperatures up to 350 degrees Celsius. This ensures that the upstream element will not be adversely affected by heating the aerosol to form the substrate. The diameter that the upstream element can have is roughly equal to the diameter of the inhaler article. The upstream element can have a substantially homogeneous structure. The upstream element can have a continuous, regular surface on its entire cross section.

[0105] When viewing the upstream end of the inhaler article, the active ingredient is not visible. Compared to conventional smoking articles where the tobacco is visible at the lit or upstream end, here, the upstream end of the upstream element is visible at the upstream end of the inhaler article. The upstream end face of the inhaler article can be used to mark with a colored mark.

[0106] The upstream element has an end face. The upstream element end face can have a colored mark. The upstream element end face can have a color as a mark. For visible, the color of the mark should be different from the color of the inhaler product itself. The upstream element can have one or more symbols as a mark. The upstream element can have both color and one or more symbols as a mark. The upstream element can have one or more colored symbols as a mark.

[0107] The strip of aerosol generating material can be a plant material. The plant material can be tobacco. Tobacco can be present in the strip as a homogenized plant material. Homogenized plant material can be provided in any suitable form. For example, homogenized plant material can exist as sheet or web material, pellet, particle, particulate, thin strip, strip, fragment or curled material. The sheet can be gathered, folded, shredded, curled or wrinkled." Tobacco particles " include ground or pulverized tobacco leaves, ground or pulverized tobacco leaf stems, tobacco dust, tobacco fines and other granular tobacco byproducts formed during the processing, disposal and transportation of tobacco. Different types of tobacco can be used, and these types of tobacco can be processed, air-dried, dried and blended to provide the preferred tobacco formulations in the strip for the aerosol generating substrate.

[0108] The aerosol generating material may comprise a compound. The aerosol generating material may comprise a pharmaceutically active compound. The aerosol generating material may comprise an active agent. In embodiments, the compound is nicotine. In embodiments, the active agent is nicotine.

[0109] The strip of aerosol-generating substrate may also include an aerosol former. This aerosol former volatilizes when heated, and the stream of aerosol former contacts the aerosol-generating substrate so as to entrain flavors and active agents from the aerosol-generating substrate in the aerosol delivered to the user. In an embodiment, the aerosol former is glycerol.

[0110] In an embodiment, the strip of aerosol generating substrate accommodates a susceptor. Preferably, the elongated susceptor has a length that is the same as or shorter than the length of the strip of aerosol generating substrate. Preferably, the elongated susceptor has the same length as the strip of aerosol generating substrate. The susceptor may be formed of any material that can be inductively heated to a temperature sufficient to generate an aerosol from the aerosol generating substrate. Preferred susceptors include metal or carbon. Preferred susceptors may include or consist of ferromagnetic materials, such as ferromagnetic alloys, ferritic iron, or ferromagnetic steel or stainless steel. Suitable susceptors may be aluminum or include aluminum. Preferred susceptors may be made of 400 series stainless steel, such as 410 grade or 420 grade or 430 grade stainless steel. When positioned in an electromagnetic field with similar frequency and field strength values, different materials will consume different amounts of energy. Therefore, the parameters of the susceptor, such as material type, length, width and thickness, may be changed in a known electromagnetic field to provide the required power consumption. Preferred susceptors may be heated to a temperature exceeding 250 degrees Celsius. A suitable susceptor may comprise a non-metallic core having a metal layer disposed on the non-metallic core, such as metal traces formed on the surface of a ceramic core. The susceptor may have an outer protective layer, such as a ceramic protective layer or a glass protective layer encapsulating the susceptor. The susceptor may comprise a protective coating formed of glass, ceramic or an inert metal, the protective coating being formed on the core of the susceptor material. The susceptor is arranged in thermal contact with the aerosol generating substrate. Thus, when the susceptor heats up, the aerosol generating substrate heats up and forms an aerosol. Preferably, the susceptor is arranged in direct physical contact with the aerosol generating substrate, such as within the aerosol generating substrate.

[0111] In an embodiment, downstream of the strip of the aerosol generating substrate is an aerosol cooling element. In an embodiment, the aerosol cooling element is a hollow section downstream of the strip of the aerosol generating substrate. The aerosol cooling element can cool the aerosol moving through the inhaler article by any means, including introducing external air into the aerosol cooling element. The aerosol cooling element is arranged to be substantially aligned with the strip of the aerosol generating substrate. The aerosol cooling element can be formed by any suitable material or material combination. For example, the aerosol cooling element can be formed by one or more materials selected from the following: cellulose acetate; cardboard, curled paper (such as curled heat-resistant paper or curled parchment); and polymer materials (such as low-density polyethylene (LDPE) or cellulose acetate). Other suitable materials include polyhydroxyalkanoate (PHA) fibers. The aerosol cooling element is between the strip of the aerosol generating substrate and the mouthpiece or barrier element.

[0112] In an embodiment, the barrier element or mouthpiece element is preferably located at the downstream end or mouth end of the inhaler article. In an embodiment, the mouthpiece element is a barrier element. In an embodiment, the barrier element is a filter. In the case where the barrier element is a filter, the filter filters the aerosol generated from the aerosol-generating substrate in the inhaler article to prevent large particles from entering the user's mouth. The barrier can be formed by segments of a fibrous filter material.

[0113] In an embodiment, the upstream element, the strip of aerosol generating substrate, the aerosol-cooling element and the barrier element are held together by an outer wrapper that defines the upstream element, the aerosol-cooling element and the barrier element. The outer wrapper may be a hydrophobic paper. The outer wrapper may be paper. The hydrophobic wrapper may be a paper layer comprising PVOH (polyvinyl alcohol) or silicon. PVOH may be applied to the paper layer as a surface coating, or the paper layer may include a surface treatment comprising PVOH or silicon.

[0114] In an embodiment, the holder comprises a cavity and a heater for receiving an inhaler article. For example, the heater is an induction heater. The induction heater comprises an induction source for generating an alternating magnetic field in the cavity for receiving an inhaler article. This magnetic field is used to induce at least one of a heating eddy current or a hysteresis loss in a susceptor, and the susceptor is positioned to be close to or directly physically contacted with the aerosol generating substrate in the strip of the aerosol generating substrate. When the magnetic field is generated, the susceptor is heated. The susceptor heats the aerosol generating substrate, and the aerosol generating substrate releases aerosol and active ingredients into the airflow that arrives the user by the inhaler article and the holder. In an embodiment, the heater is an induction coil, and wherein the induction coil is arranged around at least a portion of the receiving cavity.

[0115] The present disclosure provides a plurality of inhaler products as described above, wherein the inhaler products are packaged into a package. The present disclosure provides a package that accommodates a plurality of inhaler products. For example, a plurality of inhaler products are packaged into a package so that the end surfaces of a plurality of inhaler products are visible when the package is opened. That is to say, a plurality of inhaler products are packaged into an end surface "upwards" so that the end surface is visible at the top portion of the package when the package is opened. In an embodiment, the inhaler product is packaged into a package in an "unused" state. When the package is opened for the first time, the inhaler product is packaged into the package in an "unused" state. When the package is opened for the first time and the inhaler product is packaged into the package in an "unused" state, all inhaler products are packaged into the package in the same orientation. That is to say, when the package is assembled, a plurality of inhaler products are oriented in the package in the same manner. When the package is new, all inhaler products are packaged into the package, wherein the same end surface faces "up". When the package is new, all inhaler products can be packaged into an upstream element end surface facing upward. When the package is new, all inhaler products can be packaged into a colored mark that is visible when the package is opened. When the package is new, all inhaler articles can be packaged with the downstream component end surface facing upward.

[0116] In an embodiment, the end surface of at least one inhaler product has a colored mark.In an embodiment, the upstream end surface of at least one inhaler product has a colored mark.In an embodiment, a plurality of inhaler products are packaged in a package so that the upstream end surfaces of all inhaler products in the package are all visible when opening the package.In an embodiment, when opening the package for the first time and all inhaler products contained in the package are not used, the colored mark on the end surface of the upstream element is visible.In an embodiment, when opening the package for the first time and all inhaler products contained in the package are not used, the colored mark on the end surface of the downstream element or the barrier element is visible.When opening the package for the first time, all unused inhaler products are in the package and are not used orientation.In an embodiment, when opening the package for the first time, all unused inhaler products are in the package, and wherein the end surface has a visible colored mark.In an embodiment, when opening the package for the first time, all unused inhaler products are in the package, and wherein the upstream end surface with the colored mark is visible.

[0117] A method comprises the following steps: taking out an inhaler product from a package; inserting the inhaler product into a holder to form an inhaler system; using the inhaler system to provide a compound to a user's lungs; removing the used inhaler product from the holder; and placing the used inhaler product back into the package, wherein the used inhaler product placed back into the package in an orientation opposite to an unused orientation. The orientation opposite to the unused orientation is a "used orientation". In an embodiment, a package accommodates a plurality of inhaler products in an unused orientation. In an embodiment, a colored mark is visible on the end surface of an inhaler product packaged in the package in an unused orientation. In an embodiment, a colored mark is visible on the end surface of an inhaler product packaged in the package in an used orientation. In an embodiment, a plurality of inhaler products are arranged in the package in a mixture of an unused orientation and a used orientation. In an embodiment, in an unused orientation, a colored mark is visible (facing "up") on the end surface of an upstream element of the inhaler product in the package. In an embodiment, in the used orientation, the colored mark is not visible when the used inhaler article is placed back into the package in an orientation opposite to the unused orientation of the inhaler article in the package (facing "down"). In an embodiment, a plurality of inhaler articles are arranged in the package in a mixture of "upward" and "downward" orientations, such that the colored mark is visible on the end surface of the inhaler article arranged in the "upward" orientation, and the colored mark is not visible on the end surface of the inhaler article arranged in the "downward" orientation.

[0118] A method includes the steps of scanning the end surfaces of a plurality of inhaler articles packaged in a package in a mixture of "upward" or "unused" and "downward" or "used" orientations, and removing the inhaler articles in the "upward" or "unused" orientation for use in an inhaler system.

[0119] As used herein, the singular forms "a," "an," and "the" also encompass embodiments having plural referents, unless the content clearly dictates otherwise.

[0120] As used herein, "or" is generally employed in its sense including "and / or" unless the content clearly dictates otherwise. The term "and / or" means one or all of the listed elements or a combination of any two or more of the listed elements.

[0121] As used herein, "having", "comprising", "including", etc. are used in their open sense and generally mean "including (but not limited to)". It should be understood that "consisting essentially of", "consisting of", etc. are included in "comprising", etc.

[0122] The words "preferred" and "preferably" refer to embodiments of the invention that may provide certain benefits under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. In addition, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the present disclosure, including the claims.

[0123] As used herein, "providing" in the context of providing a device or system means manufacturing the device or system, purchasing the device or system, or otherwise acquiring the device or system.

[0124] As used herein, "or" is generally employed in its sense including "and / or" unless the content clearly dictates otherwise. The term "and / or" means one or all of the listed elements or a combination of any two or more of the listed elements.

[0125] Any directions mentioned herein, such as "top", "bottom", "left", "right", "up", "down" and other directions or orientations are described for the sake of clarity and conciseness, but are not intended to limit the actual device or system. The devices and systems described herein can be used in multiple directions and orientations.

[0126] As used herein, "downstream" and "proximal" mean the mouthpiece end of an inhaler article. "Downstream" and "proximal" mean the end of a tubular inhaler article that is intended to be contacted by the user's mouth. "Upstream" and "distal" mean the opposite end of an inhaler article. "Upstream" and "distal" mean the end of a tubular inhaler article that is intended to be inserted into a retainer.

[0127] The term "nicotine" refers to nicotine and nicotine derivatives, such as free base nicotine, nicotine salts, and the like.

[0128] As used herein, the term "closed" means fully closed before and after use to keep the capsule inside the inhaler product. "Closed" also means fully closed before or after use to reduce the loss of pharmaceutically active powder from the inhaler product. The inhaler product may be less closed after use than before use, but can still be considered closed if it provides the function of reducing the loss of the contents of the inhaler product.

[0129] As used herein, the term "use" means the steps of inserting the inhaler article into the holder, initiating airflow through the holder and the inhaler article, and delivering the active ingredient to the lungs of the user."Use" may optionally include the additional step of removing the inhaler article from the holder.

[0130] As used herein, the term "longitudinal" refers to a direction corresponding to the main longitudinal axis of the inhaler article, which direction extends between the upstream end and the downstream end of the inhaler article.

[0131] As used herein, the term "bar" indicates a generally cylindrical element having a substantially circular, oval or elliptical cross-section.

[0132] As used herein, the term "color" means any color detectable by a user. "Color" includes white.

[0133] As used herein, the term "marking" means a color or one or more symbols that are visible and recognizable to a user. The symbol may include a cutout or a flap. The marking may convey information to the user. This information may relate to the product's origin, flavor, strength, other information, or a combination thereof.

[0134] As used herein, the term "colored mark" means a color or one or more symbols visible to the user. In the case where the mark is colored, it has a color different from the color of the inhaler product. That is, if the inhaler product is white, the colored mark can be a color other than white. The white mark on the white inhaler product will be invisible to the user. In order to be visible and recognizable, the colored mark must be a color different from the inherent color of the inhaler product. Therefore, "colored mark" is any use of a color visible to the user. "Colored mark" can be a color on the surface of the inhaler product. For example, "colored mark" can mean that the end face of the inhaler product is a color different from the color of the rest of the inhaler product. Or, "colored mark" can be a shape with a color different from the color of the rest of the inhaler product. For example, "colored mark" can be a square with a color different from the color of the rest of the inhaler product. "Colored mark" can be a circle with a color different from the color of the rest of the inhaler product. "Colored mark" can be a rectangle with a color different from the color of the rest of the inhaler product. "Colored mark" can be any shape. "Colored mark" can be in the form of a symbol. That is, the symbol may be a different colour than the colour of the inhaler article. "Colored marking" and "color marking" are terms that are used interchangeably.

[0135] As used herein, the term "symbol" means a mark or character, shape, letter, picture, graphic, pictogram, emoticon or other visual element. As used herein, a "symbol" can represent or indicate an idea, including but not limited to the origin, strength, flavor or nature of a product. A symbol can be one or more symbols.

[0136] As used herein, the term "package" means a container that holds a plurality of inhaler articles.

[0137] The invention is defined in the claims. However, a non-exhaustive list of non-limiting examples is provided below. Any one or more features of these examples may be combined with any one or more features of another example, embodiment or aspect described herein.

[0138] Example Ex1: An inhaler article for insertion into a holder to form an inhaler system for providing a compound to the lungs of a user, the inhaler article comprising a tubular body extending along a longitudinal axis from a downstream mouthpiece end to an upstream end; the upstream end comprising an upstream element; the upstream element comprising an upstream end surface; wherein the upstream end surface comprises a mark.

[0139] Example Ex2: An inhaler article according to Example Ex1, wherein the marking comprises a colored marking.

[0140] Example Ex3. An inhaler article according to example Ex1 or example Ex2, wherein the marking comprises at least one symbol.

[0141] Example Ex4. An inhaler article according to any of the preceding examples, wherein the tubular body comprises, arranged in linear order from the upstream end to the downstream mouthpiece end: an upstream element; a capsule cavity containing a capsule; a capsule containing a dry powder active ingredient; a barrier element.

[0142] Example Ex5. An inhaler article according to Example Ex4, wherein the upstream element comprises an elastic element.

[0143] Example Ex6. An inhaler article according to Example Ex5, wherein the elastic element comprises an applied elastic element.

[0144] Example Ex7. An inhaler article according to Example Ex6, wherein the applied elastic element is attached to the upstream end of the tubular body.

[0145] Example Ex8. An inhaler article according to any one of Examples Ex5-Ex7, wherein the elastic element comprises indicia.

[0146] Example Ex9. The inhaler article according to any one of Examples Ex5-Ex8, wherein the elastic element comprises a cutout forming a flap.

[0147] Example Ex10. The inhaler article according to example Ex9, wherein the elastic element comprises at least 2 diameter cuts to form at least 4 flaps.

[0148] Example Ex11. An inhaler article according to example Ex9, wherein the elastic element comprises at least 3 diameter cuts to form at least 6 flaps.

[0149] Example Ex12. The inhaler article according to any one of Examples Ex9-Ex11, wherein the cutout extends in a range of about 654% to about 95% of the diameter of the elastic element.

[0150] Example Ex13. The inhaler article according to any one of Examples Ex5-Ex8, wherein the elastic element comprises a central aperture.

[0151] Example Ex14. The inhaler article according to example Ex13, wherein the diameter of the central orifice is less than 30% of the diameter of the elastic element.

[0152] Example Ex15. The inhaler article according to any one of Examples Ex5 to Ex14, wherein the elastic element comprises silicon, latex, rubber, plastic, paper, aluminum foil, paper tape, laminated layer PLA on paper layer, or cardboard.

[0153] Example Ex16. The inhaler article according to any one of Examples Ex5 to Ex15, wherein the elastic element comprises silicon, latex, rubber or a combination thereof.

[0154] Example Ex17. The inhaler article according to any one of Examples Ex1 to Ex16, wherein the barrier element comprises a filter.

[0155] Example Ex 18. The inhaler article according to any of the preceding examples, further comprising a retainer, wherein the retainer comprises a piercing element.

[0156] Example Ex19. An inhaler product according to any one of Examples Ex1-Ex3, wherein the tubular body includes, arranged in a linear order from the upstream end to the downstream mouthpiece end: an upstream element, a strip of an aerosol generating substrate located downstream of the upstream element, an aerosol cooling element located downstream of a supporting element, a barrier element located downstream of the aerosol cooling element, and an outer packaging material defining the upstream element, the aerosol cooling element and the barrier element.

[0157] Example Ex20. An inhaler article according to example Ex19, wherein the aerosol-generating substrate comprises tobacco.

[0158] Example Ex21. The inhaler article according to example Ex19 or Ex20, further comprising a holder, wherein the holder comprises a heater.

[0159] Example Ex22. An inhaler article according to example Ex21, wherein the heater comprises an induction heater.

[0160] Example Ex23. An inhaler article according to any of the preceding examples, further comprising a package containing a plurality of inhaler articles.

[0161] Example Ex 24. The inhaler article of Example 23, wherein at least one upstream end surface of at least one inhaler article contained in the package comprising indicia is visible when the package is opened.

[0162] Example Ex25. A package according to example Ex23 or example Ex24, comprising a plurality of inhaler articles according to any one of the preceding examples arranged in the package in an unused orientation.

[0163] Example Ex26. A package according to example Ex23 or example Ex24, wherein a plurality of inhaler articles are arranged in the package in a mixture of unused orientations and used orientations. BRIEF DESCRIPTION OF THE DRAWINGS

[0164] Several examples will now be further described with reference to the accompanying drawings, in which:

[0165] Figure 1A and Figure 1B An embodiment of an inhaler article having a resilient element is shown. Figure 1A An inhaler article is shown having a resilient member with flaps on the upstream end of the inhaler article. Figure 1B An inhaler article is shown having a resilient element with a central aperture on the upstream end of the inhaler article.

[0166] Figure 2 An inhaler article of the present disclosure is shown inserted into a holder to form an inhaler system.

[0167] Figure 3A and Figure 3B An inhaler article of the present disclosure is shown inserted into a holder. Figure 3A An inhaler article is shown having a resilient element at the upstream end, the resilient element being pre-cut to form flaps. Figure 3B An inhaler article inserted into a holder is shown having a resilient element at the upstream end which is pre-cut to form a flap, wherein the flap has been opened by the holder.

[0168] Figure 4A and Figure 4B An inhaler article of the present disclosure is shown inserted into a holder. Figure 4A An inhaler article is shown having a resilient element at the upstream end, the resilient element having a central aperture. Figure 4B An inhaler article inserted into a holder is shown having a resilient element at the upstream end with a central aperture, wherein the central aperture has been opened by the holder.

[0169] Figure 5Ais an embodiment of an inhaler article of the present disclosure for use in a holder having a heater. Figure 5B is an illustration of an embodiment of an inhaler article of the present disclosure engaged with an embodiment of a retainer to form an inhaler system.

[0170] Fig. 6A and Figure 6B An embodiment of a package containing a plurality of inhaler articles of the present disclosure is shown. Fig. 6A A package is shown containing a plurality of inhaler articles within the package, wherein the indicia is not visible. Figure 6B A package containing a plurality of inhaler articles is shown, several of which have visible colored indicia.

[0171] Fig. 7A , Figure 7B , Figure 7C , Fig.7D 7E, 7F and 7G illustrate embodiments of the inhaler article of the present disclosure having a resilient element at the upstream end that is pre-cut to form a flap. Fig. 7A The flap is shown folded back to form the interior opening. Figure 7B An embodiment of an inhaler article of the present disclosure is shown having a resilient element at the upstream end that is pre-cut to form a flap with either 6 radial cuts or 3 diametric cuts, thereby forming 6 flaps. Figure 7C An embodiment of an inhaler article of the present disclosure is shown having a resilient element at the upstream end that is pre-cut to form a flap with either 8 radial cuts or 4 diametric cuts, thereby forming 8 flaps. Fig.7D The embodiment of the inhaler product of the present disclosure is shown, and it has an elastic element at the upstream end, and the elastic element is pre-cut to form a flap with 6 radial cuts or 3 diameter cuts, thereby forming 6 flaps, and the ratio of the length of the cut relative to the diameter of the inhaler product is shown in an embodiment. Fig. 7E shows an embodiment of the inhaler product of the present disclosure, and it has an elastic element at the upstream end, and the elastic element is pre-cut to form a flap with 6 radial cuts or 3 diameter cuts, thereby forming 6 flaps, and the ratio of the length of the cut relative to the diameter of the inhaler product is shown in an embodiment. Fig. 7F shows an embodiment of the inhaler product of the present disclosure, and it has an elastic element at the upstream end, and the elastic element is pre-cut to form a flap with 6 radial cuts or 3 diameter cuts, thereby forming 6 flaps, and the ratio of the length of the cut relative to the diameter of the inhaler product is shown in an embodiment. Fig. 7G is a diagram of an embodiment of the inhaler product with a central orifice and a flap and having a color as a mark.

[0172] Fig. 8A , Figure 8Band Figure 8C is an illustration of an embodiment of an inhaler article of the present disclosure having colored indicia at the upstream end surface of the inhaler article. Fig. 8A is an illustration of an elastic element at the upstream end, wherein the elastic element has a central aperture, and wherein the elastic element has a color. Figure 8B is a diagram of several inhaler products with different color coding. Figure 8C is a diagrammatic representation of an inhaler article having a symbol as a marking on the upstream end face of the inhaler article.

[0173] Fig.9A , Fig. 9B 9C and 9D are illustrations of embodiments of inhaler articles 100 of the present disclosure. Fig.9A is an illustration of the resilient element 101 with the glue ring 108 applied prior to attaching the resilient element 101 to the upstream end 120 of the inhaler article 100 . Fig. 9B FIG. 9A is a photograph of an embodiment of the upstream end 120 of the inhaler article 100 prior to attaching the elastic element 101. FIG. 9C is an illustration of the elastic element 101 being applied to the upstream end 120 of the inhaler article 100. FIG. 9D is an illustration of the inhaler article 100 after the elastic element has been attached to the upstream end 120 of the inhaler article 100.

[0174] Fig. 10A , Fig. 10B and Fig. 10C A manufacturing apparatus for manufacturing an embodiment of an inhaler article having a resilient element attached to the upstream end of the inhaler article is shown. Fig. 10A A tape cutter is shown cutting out a disc of resilient material to create a resilient element. Fig. 10B A station is shown providing the glue ring during the manufacturing process. Fig. 10C The holder is shown housing three inhaler articles which are to be provided to the resilient element with the applied glue ring during the manufacturing process.

[0175] Fig.11A and Fig. 11B A manufacturing apparatus is shown for manufacturing an embodiment of an inhaler article having a resilient member attached to an upstream end of the inhaler article. Fig.11A The band cutter is shown before elastic elements of elastic material have been cut from the band of elastic material. Fig. 11B The band cutter is shown after a disc of elastomeric material has been cut from the band of elastomeric material.

[0176] Figure 12A, Figure 12B and Figure 12C show the manufacturing equipment and method for attaching the elastic element to the inhaler article in the embodiment of the inhaler article with the elastic element attached to the upstream end of the inhaler article. Figure 12A shows the step of providing the elastic element to the gluing station. Figure 12B shows the step of loading the glue ring. Figure 12C shows the step of applying glue to the elastic element.

[0177] Figure 13 A, Figure 13B and Figure 13C show the manufacturing equipment for the embodiment of the manufacture of inhaler goods, and described inhaler goods have the elastic element that is attached to the upstream end of inhaler goods.Figure 13A shows the perspective view of the elastic element with the glue ring that applies after the manufacturing step of Figure 13C.Figure 13B shows the glue side that inhaler goods is provided to the elastic element with the glue ring that applies.Figure 13C shows the inhaler goods with the elastic element that is attached to the upstream end of inhaler goods.

[0178] The schematic diagrams are not necessarily drawn to scale and are presented for illustrative rather than limiting purposes. The accompanying drawings depict one or more aspects described in the present disclosure. However, it should be understood that other aspects not depicted in the drawings fall within the scope and spirit of the present disclosure. DETAILED DESCRIPTION

[0179] Figure 1A An inhaler article 100 is shown having an upstream end 120 (also distal end), a downstream end 130 (also proximal end or mouthpiece end), a tubular body 121 extending from the downstream end 130 to the upstream end 120 along a longitudinal axis 122. The upstream end 120 has an upstream end face 152. The downstream end 130 has a downstream end face 153. The upstream end face 152 may have a colored mark 155. The downstream end face 153 may have a colored mark 155. Both the upstream end face 152 and the downstream end face 153 may have a colored mark. The mark 155 may be a colored mark 157. The mark 155 may be one or more symbols 156. The mark 155 may be both a visible color 157 and one or more symbols 156. The symbol mark 156 may be a colored symbol mark 156. Figure 1A An embodiment of an inhaler article is shown having a resilient element 101 at an upstream end 120 which is cut 104 to form a flap 103 . Figure 1AThe cutout 104 and the flap 103 formed by the cutout 104 are shown. The elastic element may have a mark 155. The elastic element may be a mark 155. For example, the elastic element may be colored and a color mark 157 may be provided. The elastic element may be a color different from the color of the rest of the inhaler article. For example, the colored mark 157 may be blue. The colored mark 157 may be red. The colored mark 157 may be orange. The colored mark 157 may be black. The colored mark 157 may be green. The colored mark 157 may be yellow. The colored mark 157 may be a design with a color different from the background color of the inhaler article 100. Alternatively, the elastic element may have at least one symbol mark 156. For example, the flap 103 is a symbol mark 156. The mark may indicate the source of the inhaler article. The mark may indicate the flavor of the inhaler article. The mark may indicate the nature of the powdered active ingredient in the inhaler article. The mark may indicate the strength of the active ingredient in the inhaler article. The mark may indicate whether the inhaler article has been used. The marking may indicate that the inhaler product is suitable for use with the holder. The marking may provide information related to the inhaler product to the user.

[0180] Figure 1A and Figure 1B Also shown is a bladder cavity 123 that houses a bladder 125 . Figure 1B An embodiment of an inhaler article is shown having a resilient element 101 at an upstream end 120 , the resilient element having a central aperture 105 . Figure 1A and Figure 1B Also shown is that the inhaler article 100 may have a barrier 131 located near the downstream end 130 of the inhaler article 100. The central aperture 105 is symbolically marked 156.

[0181] The tubular body 121 may be made of card paper or wrapping paper rolled into a tube. Figure 1A As shown in FIG. 1 , the elastic element 101 has an opening formed by cutouts 104 forming flaps 103. These cut flaps 103 provide an opening in the elastic element 101. Figure 1B , a central orifice 105 is shown. These openings provide access for a piercing needle 205 to reach and perforate the capsule 125 when the inhaler article 100 is placed in the holder 200 and the capsule 125 is activated. At the same time, these openings are smaller than the diameter of the capsule 125 to prevent the capsule 125 from falling out of the inhaler article 100 before, during or after use. Figure 1A and Figure 1B A blocker element 131 is also shown.

[0182] Figure 2Shown is the inhaler article 100 of the present disclosure that is inserted into the holder 200 and forms the inhaler system 300.The inhaler article 100 has a capsule 125, a capsule cavity 123 and a tubular body 121.The holder 200 has a housing 201 that limits a housing cavity 216.The housing cavity 216 has an open end 220 and a piercing end 221.When the inhaler article 100 is introduced into the holder 200, when entering the housing cavity 216, the inhaler article 100 is pushed against the removable cap 202 at the far end of the housing cavity 216.The removable cap 202 has a tip 210.These tips 210 can be a part of the removable cap, or can be separated from the removable cap.The tip 210 is located in the housing cavity 216.The tip 210 is configured to be inserted into the tubular body 121 of the inhaler article 100 when the inhaler article 100 is inserted into the holder 200. As shown by the arrow, the removable cap 202 moves downward relative to the housing 201. When the inhaler article and the removable cap 202 move downward relative to the housing 201, the piercing needle 205 extends through the elastic element ( Figure 2 Not shown, but see Figure 3A and Figure 3B ) and pierces the capsule 125.

[0183] There is an air inlet 206 through the housing 201 that allows air to enter the inhaler system 300. Air flows into the inhaler system 300 through the air inlet 206 in the airflow path 301, flows into the pocket 123 of the inhaler article 100 through the removable cap 202 through the airflow passage 208. Because the airflow passage 208 is tangential to the longitudinal axis 122 of the inhaler article 100 (and the pocket 123), the air flowing through the pocket 123 flows in the vortex airflow path 302. In an embodiment, there is one airflow passage 208. In an embodiment, there are two airflow passages 208. In an embodiment, there are more than two airflow passages 208.

[0184] When using this type of goods, the user will take out the inhaler goods 100 from its packaging, and the packaging may include packing 150 as shown in Figure 6. The user is inserted into the holder 200 by the inhaler goods 100 to form the inhaler system 300. When the inhaler goods 100 is inserted into the holder 200, the user presses the inhaler goods downwards, and it moves the removable cap 202 with respect to the piercing needle 205, and moves the capsule 125 contained in the capsule cavity 123 of the inhaler goods to contact the piercing needle 205, thereby piercing the capsule 125. In case the capsule 125 has been pierced, the removable cap 202 is just for example retracted by the effect of spring 212. The movement of the removable cap is indicated by arrow 215.

[0185] After piercing the capsule 125, as Figure 2123, the inhaler article 100 moves away from capsule 125. Air flows into the system via air inlet 206, through airflow path 208, through capsule cavity 123, through barrier element 131, and leaves the system to arrive the user's mouth via the downstream end 130 of inhaler article 100. The powder entrained from the capsule 125 released by being pierced is carried in the airflow path 302, and the powder is delivered to the downstream end 130 (mouthpiece end) of inhaler article 100 and is sucked by the user. This airflow is triggered by the suction provided by the user at the mouthpiece end (downstream end 130 of inhaler article 100). In addition, vortex airflow path 302 provides agitation or vortex airflow, and the agitation or vortex airflow agitates the capsule 125 inside capsule cavity 123 and improves the discharge of powder from capsule 125 during use.

[0186] Expect to be able to produce effective airflow through inhaler system 300, so that the powder of appropriate amount is entrained in the airflow, so that the powder of appropriate dose is provided to the user.Powder is discharged from capsule by the hole that is introduced into capsule 125 by piercing needle 205.This piercing needle 205 also passes the upstream end 120 of inhaler article.If the upstream end 120 of inhaler article 100 is closed, then piercing needle 205 introduces hole in the upstream end 120 of inhaler article 100.The hole produced by piercing needle 205 in the upstream end 120 of inhaler article is substantially relevant with the size of piercing needle 205.In general, the hole produced by piercing needle 205 is not large enough to make enough airflow to pass through inhaler system 300 to provide the powder of appropriate dose to the user.That is to say, the aperture in the upstream end 120 of the inhaler article 100 in the inhaler system 300 introduces significant suction resistance (RTD) into the system, and produces the system that airflow is not enough to provide the powder of appropriate dose that discharges from capsule 125 to the user. One solution to this RTD challenge is to provide an inhaler article 100 having an upstream end 120 that is open when inserted into the holder.

[0187] After using the inhaler system 300, the user can extract the inhaler product 100 from the retainer 200. After the inhaler product 100 is extracted from the retainer, the elastic element 101 recovers back to its state before use or almost its state before use. After the inhaler product 100 has been used and extracted from the retainer, the inhaler product 100 can be put back into the packaging or packaging 150. As described below Fig. 6AAs shown in, the inhaler product 100 can be packaged in the packaging, wherein the colored mark 153 on the upstream end of the product 100 faces "up" or is visible to the consumer. The inhaler product 100 can be inverted when it is put back in the packaging, so that the colored mark is invisible, and the colored mark can be a color or at least one symbol provided by the elastic element. Like this, the consumer can distinguish at a glance which products in the packaging are used. Or, the inhaler product can be packaged in the packaging, wherein the colored mark on the upstream end of the product faces "down", and is invisible to the consumer when opening the packaging. The inhaler product 100 can be inverted when it is put back in the packaging, so that the colored mark is visible, and the colored mark can be a color or at least one symbol provided by the elastic element. For example, the inhaler product can be arranged in the packaging, wherein the elastic element 101 is "downwardly" oriented, so that when the user opens the lid 151 of the packaging 150 that holds a plurality of unused inhaler products 100, the elastic element is invisible to the user. After use, when the user puts the inhaler product back in the packing, the user can invert the inhaler product used, so that the elastic element of the inhaler product used is "upwards" and visible to the user.When the inhaler product 100 used is put back in the packing, this colored mark visible to the user indicates to the user that the inhaler product of colored mark has been used.The user can distinguish the inhaler product used and the unused inhaler product in the packing then.The user can select the unused inhaler product to be used for the next dosage, and can repeat the above process.Perhaps, the inhaler product 100 can be inverted when it is put back in the packing, so that the colored mark is invisible, and the colored mark can be a color or at least one symbol provided by the elastic element.For example, the inhaler product can be arranged in the packing, wherein the elastic element 101 is "upwards" oriented, so that when the user opens the lid 151 of the packing 150 that holds a plurality of unused inhaler products 100, the elastic element is visible to the user. After use, when the user puts the inhaler product back in the packaging, the user can invert the inhaler product used, so that the elastic element of the inhaler product used is "downwards" and invisible to the user.When the inhaler product 100 used was put back in the packaging, there was no colored mark in this inverted inhaler product to indicate to the user that the inhaler product not shown in the mark was the inhaler product used. The user can distinguish the inhaler product used and the unused inhaler product in the packaging then. The user can select the unused inhaler product to be used for the next dosage, and can repeat the above process. In addition, the existence of colored mark 155 encourages the user to put the inhaler product used back in the packaging, rather than abandoning the inhaler product used in the environment. The existence of colored mark provides information to the user. The existence of colored mark has also reduced pollution.

[0188] Desirability ensures that the capsule 125 containing active ingredients is maintained in the inhaler product 100 before and after being inserted into the retainer 200. In addition, it is desirable to prevent powder from overflowing from the inhaler product 100 before and after being inserted into the retainer 200. It is desirable to prevent the capsule powder from falling out or overflowing from the inhaler product 100 before and after use. Providing an inhaler product 100 with an open upstream end 120 may not maintain the capsule 125 in the capsule cavity 123 inside the inhaler product 100. The present disclosure provides a solution to solve the RTD challenge and the challenge of keeping, and also provides information to the user and reduces pollution. These solutions are provided by a resilient element at the upstream end of the inhaler article which can be closed (or relatively closed) to hold the capsule and powder before and after insertion into the holder 200 to form the inhaler system 300, and which during use, opens during insertion into the holder 200 to provide the user of the inhaler system 300 with the proper airflow and the proper dose of powder, and which also includes colored markings that provide information to the user and can also reduce contamination.

[0189] like Figure 2 As shown in , when inserting the inhaler article into the holder, the user simultaneously moves the removable cap 202, perforates the capsule 125, and inserts the insert portion of the removable cap 202 into the inhaler article to provide an airflow orifice 140 at the upstream end 120 of the inhaler article 100, which provides the proper RTD for proper operation of the inhaler system 300. That is, when the insert portion of the removable cap is inserted into the inhaler article and the resilient element 101 is moved or stretched open, the hole at the upstream end 120 of the inhaler article 100 is large enough to enable the inhaler system to function.

[0190] In addition, when the inhaler article 100 is removed from the retainer 200, the resilient element returns to its pre-insertion state (partially or completely). When the resilient element 101 returns to its pre-insertion state, the capsule 125 and the powder are contained inside the inhaler article 100. However, the resilient element 101 including the colored marking 155 remains and can provide information to the user and can also reduce pollution.

[0191] Figure 3A and Figure 3B An inhaler article 100 having a resilient element 101 with flaps 103 is shown inserted into a holder 200. The inhaler article 100 is inserted into a housing cavity 216 of the holder 200. Figure 3A and Figure 3B The arrow in shows the insertion of the inhaler article 100 into the holder 200 . Figure 3AAn inhaler article 100 is shown having a resilient element 101 at an upstream end 120 , the resilient element having a flap 103 . Figure 3B Shown is the inhaler article 100 that is inserted in the retainer 200, it has a resilient element 101 at the upstream end 120 places, the flap 103 that said resilient element has, wherein the flap 103 has been opened 106 by the tip of the removable cap 210 of retainer 200.When flap 103 opens, airflow aperture 140 is produced.This airflow aperture 140 produces large area, so that vortex airflow flows through inhaler system 300.The flap 103 that is cut into the resilient element 101 is mark 155.That is to say, flap 103 is the symbol that is the flap shape form in the resilient element 101.

[0192] After having used the inhaler system 300, the user can withdraw the inhaler article 100 from the holder 200. After the inhaler article 100 is withdrawn from the holder and the tip of the removable cap 210 is removed from the inhaler article 100, the resilient element 101 returns to its pre-use state or nearly its pre-use state. After use, the flap 103 on the upstream end 120 of the inhaler article 100 returns to the closed state, such as, for example, Figure 1A as shown in .

[0193] Figure 4A and Figure 4B The inhaler article 100 of the present disclosure is shown inserted into a holder 200 to form an inhaler system 300 . Figure 4A and Figure 4B The arrow in shows the insertion of the inhaler article 100 into the housing cavity 216 of the holder 200 . Figure 4A An inhaler article 100 is shown having a resilient element 101 at an upstream end 120 , the resilient element 101 having a central aperture 105 . Figure 4B Shown is the inhaler product 100 that is inserted into the retainer 200, it has elastic element 101 at upstream end 120 places, and described elastic element has central aperture 105, and wherein central aperture 105 has been opened to form airflow aperture 140.By the tip of removable cap 210 is inserted into the central aperture 105 of the elastic element 101 that passes through inhaler product 100, central aperture 105 has been opened to form airflow aperture 140.The central aperture 105 that is arranged in the elastic element 101 is mark 155.That is to say, central aperture 105 is the symbol that is the central aperture shape form in the elastic element 101.In an embodiment, the diameter of central aperture 105 can be approximately 30% of the diameter of elastic element.In an embodiment, the diameter of central aperture can be less than 30% of the diameter of elastic element.

[0194] After having used the inhaler system 300, the user can withdraw the inhaler article 100 from the holder 200. After the inhaler article 100 is withdrawn from the holder and the tip of the removable cap 210 is removed from the inhaler article 100, the resilient element 101 returns to its pre-use state or nearly its pre-use state. After use, the central aperture 105 of the resilient element 101 returns to a closed state, such as, for example, Figure 1B .When the inhaler product 100 was removed from the retainer 200, the elastic element returned to its state before insertion (partially or completely).When the elastic element 101 returned to its state before insertion, capsule 125 and powder were contained in the inhaler product 100 insides.Yet, the elastic element 101 comprising mark 155 keeps, and can provide information to the user, and can also reduce pollution.

[0195] Figure 5A is an embodiment of an inhaler article of the present disclosure for use in a holder having a heater. Figure 5A The inhaler article 100 shown in the figure comprises a strip 12 of an aerosol generating substrate 12 and a downstream section 14 at a position downstream of the strip 12 of the aerosol generating substrate. In addition, the inhaler article 100 comprises an upstream section 16 at a position upstream of the strip 12 of the aerosol generating substrate. Therefore, the inhaler article 100 extends from the upstream end face 152 and the upstream element 18 to the downstream end or mouth end 130 having the downstream end face 153. The inhaler article has an overall length of about 45 millimeters. The downstream section 14 comprises a supporting element 22 positioned downstream of the strip 12 of the aerosol generating substrate, and the supporting element 22 is longitudinally aligned with the strip 12. In Figure 5A In the embodiment of the invention, the upstream element 18 abuts the upstream end of the strip 12 of aerosol-generating substrate. In addition, the downstream section 14 includes an aerosol-cooling element 24 positioned immediately downstream of the support element 22, the aerosol-cooling element 24 being longitudinally aligned with the strip 12 and the support element 22. Figure 5A In the embodiment of the invention, the upstream end of the aerosol-cooling element 24 is adjacent to the downstream end of the support element 22. In this embodiment, the inhaler article has an upstream element 18.

[0196] The support element 22 and the aerosol-cooling element 24 together define the middle hollow section 50 of the inhaler article 100. The support element 22 includes a first hollow tubular segment 26. The first hollow tubular segment 26 is provided in the form of a hollow cylindrical tube made of cellulose acetate. The first hollow tubular segment 26 defines an inner cavity 28 extending from the upstream end 30 of the first hollow tubular segment to the downstream end 32 of the first hollow tubular segment 26. The inner cavity 28 is substantially empty, and thus substantially unrestricted airflow is achieved along the inner cavity 28. The aerosol-cooling element 24 includes a second hollow tubular segment 34. The second hollow tubular segment 34 is provided in the form of a hollow cylindrical tube made of cellulose acetate. The second hollow tubular segment 34 defines an inner cavity 36 extending from the upstream end 38 of the second hollow tubular segment to the downstream end 40 of the second hollow tubular segment 34. The inner cavity 36 is substantially hollow, and thus substantially unrestricted airflow is achieved along the inner cavity 36. The downstream section 14 further comprises a barrier element 131 at a position downstream of the intermediate hollow section 50. In more detail, the barrier element 131 is positioned immediately downstream of the aerosol-cooling element 24. Figure 5A As shown in the accompanying drawings of , the upstream end of the barrier element 131 abuts the downstream end 40 of the aerosol-cooling element 24. The barrier element 131 is provided in the form of a cylindrical rod of low-density cellulose acetate. The barrier element 131 can be a filter. The barrier element 131 has a length of about 12 mm and an outer diameter of about 7.25 mm. The RTD of the mouthpiece element 131 is about 12 1 0 mm H2O. The strip 12 includes an aerosol-generating substrate of one of the above-mentioned types. The strip 12 of the aerosol-generating substrate has an outer diameter of about 7.25 mm and a length of about 12 mm.

[0197] The inhaler article 100 also includes an elongated susceptor 44 within the strip 12 of aerosol generating substrate. In more detail, the susceptor 44 is substantially longitudinally arranged within the aerosol generating substrate so as to be approximately parallel to the longitudinal direction of the strip 12. The susceptor 44 is positioned in a radially central position within the strip and effectively extends along the longitudinal axis of the strip 12. The susceptor 44 extends from the upstream end of the strip 12 all the way to the downstream end. In fact, the susceptor 44 has substantially the same length as the strip 12 of aerosol generating substrate.

[0198] exist Figure 5A In the embodiment of the invention, the susceptor 44 is provided in the form of a strip and has a length of about 12 mm, a thickness of about 60 μm and a width of about 4 mm. The upstream section 16 comprises an upstream element 18 positioned immediately upstream of the strip 12 of the aerosol generating substrate, the upstream element 18 being longitudinally aligned with the strip 12. Figure 5AIn the embodiment of the invention, the downstream end of the upstream element 18 abuts the upstream end of the strip 12 of aerosol-generating substrate. This advantageously prevents the susceptor 44 from being removed. Furthermore, this ensures that the consumer does not accidentally contact the heated susceptor 44 after use. The upstream element 18 is provided in the form of a cylindrical cellulose acetate rod defined by a rigid wrapper. The upstream element 18 has a length of about 5 mm.

[0199] Figure 5B is an illustration of an embodiment of an inhaler article 100 of the present disclosure engaged with an embodiment of a retainer 200 to form an inhaler system 300. Figure 5B As shown in Figure 5A Inhaler article 100 is inserted into the holder 200 with the cavity 120 for receiving and accommodating the inhaler article 100. Holder 200 comprises power source 160 (for example lithium ion battery) and circuit 170, and this circuit comprises controller, is used to control the operation of inhaler system 300, particularly is used to control heating process. Holder 200 comprises induction source, and this induction source comprises induction coil 310, is used to produce alternating, particularly high frequency magnetic field. Induction coil 310 is the spiral coil around cylindrical receiving cavity 120 circumferentially. Induction coil 310 is formed by wire 380 and has a plurality of turns or windings extending along its length. Wire 380 has a circular cross section. In other embodiments, wire can have a flat cross-section shape.

[0200] In use, when the device is activated, Figure 5A and Figure 5B The embodiment of the induction coil 310 is passed through a high frequency alternating current. This causes the coil 310 to generate an alternating magnetic field within the chamber 120. Therefore, depending on the magnetic and electrical properties of the material of the susceptor element 44, the susceptor 44 located in the strip 12 of the aerosol generating substrate becomes hot due to at least one of eddy currents or hysteresis losses. The susceptor 44 then heats the strip 12 of the aerosol generating substrate to a temperature sufficient to form an aerosol. The aerosol can be drawn downstream through the inhaler article 100 for inhalation by the user.

[0201] In an embodiment, the upstream end face 152 of the inhaler product 100 comprises a colored mark 155. In an embodiment, the downstream end face 153 of the inhaler product 100 comprises a colored mark. In an embodiment, the upstream end face 152 and the downstream end face 153 of the inhaler product both comprise a colored mark 155. In an embodiment, the mark 155 is a color mark 157. In an embodiment, the mark 155 is at least one symbol 156. In an embodiment, the mark is both a color 157 and at least one symbol 156. In an embodiment, the colored mark 155 on the upstream end face 152 is different in color from the colored mark 155 on the downstream end face 153 of the inhaler product 100.

[0202] In an embodiment, the inhaler article comprises a tubular body comprising, arranged in linear order from an upstream end to a downstream mouthpiece end: an upstream element, a strip of an aerosol-generating substrate downstream of the upstream element, an aerosol-cooling element downstream of the strip of the aerosol-generating substrate, a barrier element downstream of the aerosol-cooling element, and an outer wrapper defining the upstream element, the aerosol-cooling element, and the barrier element.

[0203] Fig. 6A and Figure 6B It is a diagram of a plurality of inhaler products 100 of the present disclosure that are packaged in the packaging 150.Package 150 has a lid 151.When opening the lid 151 of packaging 150, the end faces of a plurality of inhaler products 100 are visible to the user.The visible end face when opening the lid 151 of packaging is "upwards".The invisible end face when opening the lid 151 of packaging 150, the end face that is inserted into the packaging, these end faces are "downwards".The visible end face can be an upstream end face 152 or a downstream end face 153, and this depends on the orientation of the inhaler products when being packaged in the packaging 150.Initially, when the inhaler products were packaged in the packaging 150 during manufacture, all inhaler products were initially packaged in the packaging with the same orientation.That is to say, the upstream end face 152 or the downstream end face 153 will be "upwards" and visible when opening the lid 151 of packaging 150.

[0204] Fig. 6A is a diagram showing an inhaler article 100 packaged into a package 150. Fig. 6A In the embodiment, the indicia 155 is visible when the cover 151 of the package 150 is opened. That is, the indicia 155 is oriented "upward" in the package. In this embodiment, the inhaler product has the indicia 155 on the upstream end face 152 and no indicia on the downstream end face 153. Fig. 6A As shown in FIG. 1 , the upstream end face 152 is upward and the downstream end face 153 is downward. The downstream end face 153 does not have the marking 155. The opposite end face, the upstream end face 152, faces "upward" and is visible with the lid of the package 150 opened. Fig. 6A As shown in FIG. 1 , the mark 155 is visible when the cover 151 of the package 150 is opened. Fig. 6A In this illustration of the inhaler article 100, the inhaler article 100 is packaged into a package with the upstream end inside the package (the upstream end is "upward"), and the downstream end face 153 is at the bottom of the package and is not visible when the cover 151 of the package 150 is opened (the downstream end face 153 is "upward"). That is, as Fig. 6A As shown in FIG. 1 , the inhaler articles are packaged into package 150 with the upstream end facing upward.

[0205] In an embodiment, the inhaler product can be packaged into the package 150 with the upstream end face 152 downward and the downstream end face 153 upward. That is, in an embodiment, the inhaler product can be packaged into the package so that the consumer sees the downstream end face 153 when opening the package. In an embodiment, the downstream end face 153 has a colored mark 155.

[0206] Figure 6B Some visible end surfaces of the multiple inhaler articles 100 are shown to have colored markings 155 visible when the cover 151 of the package 150 is opened. The markings 155 can be colored markings 157. For example, the colored markings 157 can be blue. The colored markings 157 can be red. The colored markings 157 can be orange. The colored markings 157 can be black. The colored markings 157 can be green. The colored markings 157 can be yellow. The colored markings 157 can be designs with a color different from the background color of the inhaler article 100. The marking can be a symbol marking 156. The marking can be both a color 157 and a symbol 156 marking. The marking can be on the elastic element 101. In Fig. 6A and Figure 6B In the embodiment shown in , the indicia 155 is present on the upstream end face 152 of the inhaler article 100 , and the indicia 155 is absent on the downstream end face 153 of the inhaler article 100 .

[0207] like Figure 6B As shown in FIG. 1 , a package 150 may contain some inhaler products 100 in the package 150, wherein the downstream end 153 without indicia faces upward. Also, the same package 150 may contain some inhaler products 100 in the package 150, wherein the upstream end 152 with indicia 155 faces upward. That is, as Figure 6B As shown in , some of the inhaler products 100 are inverted in the package. In this way, the markings 155 on the upstream end face 152 of these inverted inhaler products are visible when the lid 151 of the package 150 is opened. Fig. 6A As shown in , this may occur when a user takes out an inhaler product from a new package 150, wherein all inhaler products 100 are packaged into the package 150, wherein the visible markings on the upstream end face 152 face upward. The user then uses the inhaler product that has been taken out of the package 150. When the user puts the used inhaler product back into the package 150, the user inverts the used inhaler product 100 and places the used inhaler product 100 into the package, wherein the downstream face 153 without markings 155 faces "up". In other words, when the user puts the used inhaler product back into the package 150, the user inverts the inhaler product. As shown in FIG. Figure 6BAs can be seen in the figure, some of the inhaler product 100 have visible markings 155, and some of the inhaler product do not have visible markings.When the user takes out the next inhaler product from packaging, the user can see which inhaler products have been used, because the inhaler product used is inverted in packaging, and the mark 155 on the upstream end face 152 of unused inhaler product 100 indicates to the user that the inhaler product 100 with visible markings 155 is new.The inhaler product that does not have visible markings, the inhaler product that was inverted when the inhaler product was reinserted into the packaging is used.This enables the user to easily distinguish between the new inhaler product 100 and the used inhaler product that is contained in the packaging 150.Because the user can distinguish the new inhaler product in the packaging and the used inhaler product, therefore the user is more likely to put the used inhaler product back in the packaging, and unlikely the used inhaler product is discarded in the environment.

[0208] Fig. 7A , Figure 7B , Figure 7C , Fig.7D 7E, 7F and 7G show an embodiment of the inhaler article of the present disclosure having a resilient element 101 at the upstream end, the resilient element being cut to form a flap 103. The number of cuts 104 and the length of the cuts 104 define the geometry of the flap 103 formed by the cuts 104. Fig. 7A The flap 103 is shown folded back to form an interior opening. Fig. 7A The number of cutouts 104 defining the shape of the arc 135, the flap 103, is shown, wherein the flap folds inwardly. Figure 7B 3 diameter cuts or 6 radial cuts as shown in Figure 7C 8 radial cuts or 4 diametric cuts as shown in FIG. 1 ) changes arc 135. Increasing the number of cuts reduces arc 135. For example, Figure 7B An elastic element having 3 diametric cuts or 6 radial cuts to form 6 flaps is shown. Figure 7CAs shown in , the resulting arc 135 of the elastic element with 6 flaps is greater than the arc produced by the same size elastic element with 4 diameter cuts or 8 radial cuts to form 8 flaps. Increasing the number of cuts 104, and therefore increasing the number of flaps 103, reduces the arc 135. In addition, the length of the cut 104 affects the arc 135. Changing the geometry of these flaps and reducing the arc 135 can make it possible to use different materials for the elastic element 101. For example, providing more flaps reduces the arc and can allow the elastic material to be less elastic and still return to its original shape or almost its original shape after opening the flap 103. For example, if there are more flaps and smaller arcs, cardboard can be an appropriate material. If there are 4 or 6 flaps, the material may need to be more elastic, such as silicon, latex, rubber or plastic. In an embodiment, the elastic material can be, for example, silicon, latex, rubber, plastic, paper, aluminum foil, paper tape, laminated layer PLA on paper layer or cardboard. In case more elasticity is required, the material may be selected from silicone, latex, rubber or a combination.In an embodiment, the thickness of the elastic element may be, for example, less than 0.5 mm.

[0209] In addition, if Fig.7D , 7E and 7F, the length of the cutouts may also affect the size and shape of the flaps and arcs 135. The size of the flaps 103, the length of the cutouts 104 and the geometry of the arcs 135 may be adjusted in association with the material of the resilient element to optimize the ability of the resilient element to close before and after use and to open to form a suitable airflow path during use when the inhaler article 100 is inserted into the holder 200 to form the inhaler system 300. Fig.7D , 7E and 7F show a pre-cut 104 forming a flap 103, wherein the pre-cut extends about 90% of the diameter of the inhaler article ( Fig.7D ), about 78% (Fig. 7 E) of the diameter of inhaler products and about 65% (Fig. 7 F) of inhaler products.Fig. 7 G is the diagram of the embodiment of the inhaler products with central aperture 105 and flap 103.In an embodiment, elastic element 101 is precut to form at least 4 flaps.In an embodiment, elastic element 101 is precut to form at least 6 flaps.In an embodiment, elastic element 101 is precut to form 4,6 or 8 flaps.The flap of this number provides the arc region of elastic element to provide (when being pushed in retainer 200) good flexibility and tear resistance, and the suitable rigidity that returns to its initial position when goods are removed from retainer 200.In an embodiment, the incision extends about 65% to 95% of the diameter of elastic element 101.

[0210] In an embodiment, the cuts are of equal length and cross at the center of the resilient element, and have similar angles between the cuts, thereby providing a symmetrical distribution of forces applied to the flaps when pushed into the holder 200. Providing this symmetry can help prevent tearing of the resilient element when inserting the inhaler article into the holder, and can help with the desired opening and closing of the resilient element.

[0211] In an embodiment, the cutout 104 of the elastic element 101 is a mark 155. That is, the cutout of the elastic element is a symbol mark 156. In an embodiment, the flap 103 of the elastic element 101 is a symbol mark 156. In an embodiment, the elastic element is colored and has a color mark 157. In an embodiment, the elastic element 103 has both a color mark 157 and a symbol mark 156. The elastic element as shown in Figure 7 provides a mark 155.

[0212] Fig. 8A is an illustration of an embodiment of an inhaler article 100 of the present disclosure having a resilient element 101 at an upstream end forming an upstream end surface 152 , wherein the resilient element has a central aperture 105 . Fig. 8A It is shown that the resilient element 101 may form an upstream end face 152 of an inhaler article. The resilient element may be coloured to provide colour indicia 157. The central aperture 105 may provide symbol indicia 156. Figure 8B 1 is another illustration of an inhaler article 100 of the present disclosure having a resilient element 101 at the upstream end, wherein a plurality of inhaler articles 100 may have a plurality of color indicia 157. That is, different colors may be used for the color indicia 157. These colors may indicate different sources, different flavors, different strengths, or other information to the user. Figure 8C is an illustration of the embodiment of the inhaler article 100 of FIG. 5 having indicia 155 at the upstream end face 152 of the upstream element 18 . Figure 8C The marking 155 is shown to be a symbolic marking 156. However, a color marking 157 may also be used. In an embodiment, the diameter of the central hole may be about 30% of the diameter of the disc, less than 30%.

[0213] Fig.9A , Fig. 9B 9C and 9D are illustrations of embodiments of inhaler articles 100 of the present disclosure. Fig.9A is an illustration of the resilient element 101 with the glue ring 108 applied prior to attaching the resilient element 101 to the upstream end 120 of the inhaler article 100 . Figure 8BFIG. 9 is a photograph of an embodiment of the upstream end 120 of the inhaler article 100 prior to attaching the elastic element 101. FIG. 9C is an illustration of the elastic element 101 being applied to the upstream end 120 of the inhaler article 100. FIG. 9D shows an illustration of the inhaler article 100 after the elastic element has been attached to the upstream end 120 of the inhaler article 100.

[0214] Fig. 10A , Fig. 10B and Fig. 10C A manufacturing apparatus 400 and method for manufacturing an embodiment of an inhaler article 100 having an elastic element 101 attached to the upstream end 120 of the inhaler article 100 is shown. This manufacturing apparatus 400 operates to cut out a disk of elastic material to form the elastic element 101 that fits at the upstream end 120 of the inhaler article 100. Fig. 10A A tape cutter 403 is shown having a feeder reel 401, tape 402, a cutter 403, a cutter station 405 and a take-up reel 404. In use, as Fig. 10A , a feeder reel 401 contains an uncut elastic material strip 402. This uncut elastic material strip 402 is provided to a tape cutter 403 on a cutter station 405. The cutter 403 cuts a disk of elastic material to produce an elastic element 101. In addition, the cutter 403 can cut in the elastic element to form a flap 103, thereby manufacturing an elastic element 101 with a flap 103. Alternatively, the cutter 403 can cut a central aperture 105 in the disk to form an elastic element 101 with a central aperture 105. Alternatively, the cut 104 or the central aperture 105 can be produced in the elastic element 101 in a separate cutting step or assembly step. After the disk is cut from the tape 402, the used tape 406 travels to the take-up reel 404. Fig. 10B A glue station 500 is shown with a glue stage which optionally provides a glue ring to the disc or elastic element during the manufacturing process. Fig. 10C The element holder 600 is shown holding three resilient elements which, in use, are provided to a glue station 502 for applying glue to cut resilient elements during the manufacturing process.

[0215] Fig.11A and Fig. 11B A manufacturing apparatus and method for manufacturing an embodiment of an inhaler article 100 having a resilient element 101 attached to an upstream end 120 of the inhaler article 100 is shown. Fig.11AThe cutting step is shown where a strip of elastic material 402 is provided to a cutting station 405 and a strip cutter 403 is aimed at the cutting station 405 with the strip of elastic material 402. The strip cutter 403 cuts a disc of elastic material from the strip of elastic material 402. The cutting may be performed by press cutting, knife cutting, laser cutting, or by any means. Fig. 11B Shown is the step of removing the elastic material disk from cutting station 405.Once cutting has been carried out, the elastic material disk can be removed from cutting station 405 to proceed to the next step in the manufacturing process.In addition, cutting tape 406 proceeds to the take-up reel, and new uncut tape will be provided to cutter station 405 so that the cutting step can be repeated.The cutting step can also include cutting a line in the elastic element to form a flap, or cutting a central aperture in the elastic element, or cutting a combination of a central aperture and a flap in the elastic element.The cutting step can also include cutting a mark 155 into the elastic element 101.The cutting step can include cutting a line, a flap or a central aperture into the elastic element.The cutting line 104, a flap 103 or a central aperture 105 can be a mark 155.

[0216] Figures 12A, 12B and 12C show a manufacturing apparatus and method for manufacturing an embodiment of an inhaler article 100 having an elastic element 101 attached to an upstream end 120 of the inhaler article 100. Figures 12A, 12B and 12B show the gluing step of the manufacturing process. Figure 12A shows the step of providing the elastic element to the gluing station. Figure 12B shows the step of loading the glue ring 502. The glue can be extruded onto the stage from a glue reservoir located below the glue station. Alternatively, the glue can be provided in dots, discontinuous rings, thick rings, thin rings or any other shape to provide glue to the glue station. Figure 12C shows the step of applying glue to the elastic element. Figure 12A shows the step of providing the cut elastic element 101 to the glue station 500. The glue station 501 has a glue ring 502. The elastic element 101 is provided to the glue station 501 on the element holder 600. Figure 12A shows the glue ring 502 before the glue has been provided to the glue ring 502. FIG. 12B shows the glue stage 501 and the glue ring 502 after glue has been provided to the glue ring 502. In other words, as shown in FIG. 12B , the glue ring has been loaded with glue. In an embodiment, glue may be provided to the glue ring 502 by pressing glue from a glue reservoir below the glue stage 501 into the glue ring 502. FIG. 12C shows the step of pressing the cut elastic element 101 onto the glue stage 501 to provide glue to the elastic element 101. Suitable glue may include a starch adhesive such as dextrin, a casein-based adhesive, polyamide blue, hot melt glue, cyanoacrylate, organic glue, or any other suitable glue.

[0217] Figure 13A, Figure 13B and Figure 13C show the manufacturing equipment and method for the embodiment of the manufacture of inhaler products, and the inhaler products have the elastic element 101 attached to the upstream end 120 of the inhaler products 100. Figure 13A shows the perspective view of the elastic element 101 with the glue ring 503 applied after the manufacturing step of Figure 12C. Figure 13B shows that the inhaler products 100 are provided to the glue side of the elastic element 101 with the glue ring 503 applied. Figure 13C shows the inhaler products with the elastic element 101 attached to the upstream end 120 of the inhaler products 100. In an embodiment, the elastic element 101 is an upstream element. In an embodiment, the elastic element 101 comprises a mark 155. In an embodiment, the mark is a color mark 157. In an embodiment, the mark is a symbol mark 156. In an embodiment, the elastic element 101 comprises both color and symbol mark.

[0218] For the purpose of this specification and the appended claims, unless otherwise stated, all numbers representing amounts, quantities, percentages, etc. should be understood to be modified by the term "about" in all cases. In addition, all ranges include the disclosed maximum and minimum points, and include any intermediate ranges therein, which may or may not be specifically listed in this article. Therefore, in this context, the number A is understood to be A±10%A. In this context, the number A can be regarded as including a value within the general standard error for the measurement of the attribute modified by the number A. In some cases used in the appended claims, the number A may deviate from the percentages listed above, provided that the amount of A deviation will not substantially affect the basic characteristics and novel features of the claimed invention. In addition, all ranges include the disclosed maximum and minimum points, and include any intermediate ranges therein, which may or may not be specifically listed in this article.

Claims

1. An inhaler article for insertion into a holder to form an inhaler system for providing a compound to the lungs of a user, the inhaler article comprising: a tubular body extending along a longitudinal axis from a downstream mouthpiece end to an upstream end; The upstream end includes an upstream element; The upstream element includes an upstream end surface; and Wherein the upstream end surface includes colored markings.

2. The inhaler article of claim 1, wherein the colored indicia comprises at least one symbol.

3. The inhaler article of any one of the preceding claims, wherein the tubular body comprises, arranged in linear order from the upstream end to the downstream mouthpiece end: the upstream element; The cystic cavity that holds the cyst; said capsule containing a dry powder active ingredient; and, Blocker element.

4. The inhaler article of claim 3, wherein the upstream element comprises a resilient element.

5. The inhaler article of claim 4, wherein the resilient element is attached to the upstream end of the tubular body.

6. An inhaler article according to any one of claims 4 or 5, wherein the resilient element comprises a cutout forming a flap.

7. The inhaler article of any one of claims 4-6, wherein the resilient element comprises a central aperture.

8. The inhaler article of any one of claims 4-7, wherein the resilient element comprises silicone, latex, rubber, or a combination thereof.

9. The inhaler article of any one of claims 3-8, wherein the barrier element comprises a filter.

10. The inhaler article of any one of claims 1-3, wherein the tubular body comprises, arranged in linear order from the upstream end to the downstream mouthpiece end: The upstream element, a strip of aerosol-generating substrate located downstream of said upstream element, an aerosol-cooling element located downstream of the strip of aerosol-generating substrate, a barrier element located downstream of the aerosol-cooling element, and An outer wrapper defines the upstream element, the aerosol-cooling element and the barrier element.

11. The inhaler article of any one of claims 4-8, wherein the resilient element opens to an open position in response to an opening force and closes to a closed position when the opening force is removed; Wherein when the resilient element is in the closed position, the resilient element is sufficiently closed to retain the capsule in the capsule cavity between the downstream mouthpiece end and the resilient element.

12. An inhaler system comprising: a retainer, wherein the retainer comprises a piercing element; and, An inhaler article according to any preceding claim inserted into the holder.

13. The inhaler system of claim 12, wherein the retainer provides an opening force to open the upstream element.

14. An inhaler system according to claim 12 or claim 13, wherein the holder comprises a heater.

15. A package containing a plurality of inhaler articles according to any one of claims 1 to 11, and wherein at least one upstream end surface of at least one inhaler article contained in the package comprising coloured indicia is visible when the package is opened.

Images